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Riassunto 
 
La fenilchetonuria (PKU) è una malattia genetica, dovuta a mutazioni del gene codificante 
l’enzima fenilalanina idrossilasi (PAH), che catalizza l'idrossilazione della fenilalanina (Phe) in 
tirosina. Una ridotta attività di PAH, porta ad elevate concentrazioni di fenilalanina nel sangue, 
nei fluidi corporei e a concentrazioni cerebrali tossiche (Blau 2016). Nonostante ci siano continui 
progressi nelle terapie, la restrizione della Phe dalla dieta rimane l’elemento cardine nella 
gestione della PKU (Giovannini et al. 2012). Le differenti combinazioni di mutazioni di PAH 
portano a diversi fenotipi metabolici che vanno dall’ iperfenilalaninemia lieve (MHP), nella 
quale restrizione dietetica non è necessaria, alla PKU lieve, moderata e classica, che richiedono il 
trattamento dietetico (Regier, Greene 2000). La dieta per le persone affette da PKU è composta 
da alimenti a basso contenuto di proteine naturali (ortaggi, frutta), prodotti speciali a basso 
contenuto proteico (varianti a basso contenuto proteico di alcuni alimenti come pane, pasta e 
biscotti) e miscele amminoacidiche Phe-free, che forniscono gli amminoacidi in opportune 
proporzioni (Giovannini et al. 2012). 
Poiché i bambini affetti da PKU devono iniziare il trattamento dietetico pochi giorni dopo la 
nascita e lo devono seguire per tutta la vita, risulta importante analizzare la sicurezza a lungo 
termine di questo trattamento dietetico e il suo potenziale impatto sul successivo rischio di non-
communicable diseases. 
L'obiettivo generale di questa tesi di dottorato è stato quello di studiare l'impatto della dieta 
“PKU”, in modo particolare la qualità dei carboidrati, sui fattori di rischio cardiovascolare e sulla 
produzione di acidi grassi a corta catena (SCFA) fecali in bambini affetti da fenilchetonuria. 
I risultati principali sono stati: 1) nei bambini PKU il trattamento dietetico potrebbe essere 
associato ad un più elevato indice e carico glicemico giornaliero, ad un’elevata assunzione di 
carboidrati e fibre e ad una bassa assunzione di proteine rispetto bambini sani. Inoltre, nei 
bambini PKU potrebbe esserci un’associazione tra la qualità dei carboidrati consumati e il 
tryglicerid glucose index, che sembra indicare insulino-resistenza periferica. 2) Per quanto 
riguarda i fattori di rischio cardiovascolare, è stato osservato: uno spessore dell’intima media 
carotidea più sottile, minori livelli di colesterolo totale, colesterolo LDL e di omocisteina e un 
basso in bambini PKU rispetto ai bambini sani. Al contrario, in bambini PKU sono stati osservati 
elevati i livelli ematici di trigliceridi, l’atherogenic index of plasma e il rapporto trigliceridi/HDL 
rispetto ai bambini sani. Nel gruppo PKU, non sono state osservate associazioni tra lo spessore 
dell’intima media carotidea e l’indice glicemico e il carico glicemico giornalieri. 3) Dal 
confronto tra la biodiversità del microbiota intestinale e la sua produzione di SCFA in bambini 
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PKU con quella di bambini MHP è emerso che i bambini PKU hanno una ridotta biodiversità del 
microbiota intestinale e una minore produzione fecale di SCFA, sia totale che di butirrato, 
rispetto ai bambini MHP.  
In conclusione, dovrebbe essere posta una maggiore attenzione alla qualità dei carboidrati 
presenti nella dieta “PKU”, in modo particolare nei prodotti speciali a basso contenuto proteico. 
Studi longitudinali, adeguatamente progettati, sono necessari per chiarire le relazioni tra la dieta 
con un limitato apporto di fenilalanina e i fattori di rischio cardiovascolare/variabili metaboliche 
in bambini affetti da PKU. Inoltre, ulteriori studi, che utilizzano tecniche di sequenziamento 
innovative, sono necessari per indagare meglio disbiosi del microbiota intestinale nei bambini 
affetti da PKU e per poter aprire la strada ad integrazioni di pre/probiotici in questa popolazione. 
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Abstract 
 
Phenylketonuria (PKU) is a genetic disorder, caused by mutations in the gene encoding 
phenylalanine hydroxylase (PAH). PAH catalyzes the hydroxylation of phenylalanine (Phe) to 
tyrosine. Loss of PAH activity results in increased concentrations of phenylalanine in the blood 
and fluids throughout the body and toxic concentrations in the brain (Blau 2016). Despite 
continuing progress in the treatment, the restriction of dietary Phe remains the mainstay of PKU 
management (Giovannini et al. 2012). Various combinations of PAH mutations result in a full 
spectrum of metabolic phenotypes ranging from mild hyperphenylalaninemia (MHP), in which 
dietary restriction is not necessary to mild, moderate and classical phenylketonuria, which 
require dietary management (Regier, Greene 2000). PKU diet is mainly made up of low-protein 
natural foods (vegetables, fruits), special low protein products (low-protein variants of some 
foods such as bread, pasta and biscuits) and Phe-free protein substitutes, which provide amino 
acids in suitable proportions (Giovannini et al. 2012). 
Because PKU children have to start a Phe restricted diet as soon as possible and to follow this 
throughout life, the long-term safety of this dietary treatment and its potential impact on later 
non-communicable diseases risk need to be better evaluated. 
The general aim of this PhD thesis was to investigate the impact of phenylketonuric diet, 
principally carbohydrates quality, on cardiovascular risk factors and fecal short chain fatty acids 
(SCFA) production in children with phenylketonuria. 
The key findings were: 1) in PKU children the dietary treatment could be associated with higher 
overall glycemic index and load, fiber and carbohydrate intakes and lower protein intakes than 
healthy children. Moreover, in PKU children a relationship between the quality of carbohydrates 
consumed and the triglyceride glucose index, that seems to reflect mainly peripheral insulin 
resistance, may exist. 2) Regarding cardiovascular risk factors, PKU children showed a thinner 
intima media thickness, lower total cholesterol, LDL cholesterol and homocysteine levels than 
healthy children. Conversely, PKU children had higher triglyceride levels, atherogenic index of 
plasma and higher triglycerides/HDL ratio than healthy children. In PKU group, no associations 
of intima media thickness with overall glycemic index and glycemic load were observed. 3) 
Comparing gut microbiota biodiversity and its production of SCFA in PKU children and MHP 
children, PKU children showed a lower degree of microbial diversity in gut microbiota and 
minor total fecal SCFA and butyrate production than MHP children.  
In conclusion, a greater attention should be paid to the management of dietary carbohydrate 
quality in PKU diet, with focus on special low protein products. Longitudinal, adequately-
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powered studies are needed to clarify the interrelationships between the diet and cardiovascular 
risk factors/metabolic profile of PKU children. Moreover, further studies using innovative 
sequencing techniques are needed to better investigate gut microbiota dysbiosis in PKU children 
and to eventually pave the way for pre/probiotic supplementations in this population. 
 
• Blau N. Genetics of Phenylketonuria: Then and Now. Hum Mutat. 2016;37(6):508-15. 
• Giovannini M., Verduci E, Salvatici E, Paci S, Riva, E. Phenylketonuria: nutritional 
advances and challenges. Nutr Metab. 2012; 9:1-7. 
• Regier DS, Greene CL. Phenylalanine Hydroxylase Deficiency. 2000 Jan 10 [Updated 
2017 Jan 5]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® 
[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. 
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1.1 Phenylketonuria and dietary treatment 
 
1.1.1 Phenylketonoria: overview 
 
Phenylketonuria (PKU; OMIM 261 600) is an autosomal recessive disorder of Phenylalanine 
(Phe) metabolism [1], caused by mutations of phenylalanine hydroxylase (PAH) gene, which is 
located on the long arm of chromosome 12 in the band region q22-q24 (Figure 1). Until now, 
over 950 different mutations have been identified [2,3]. With an average incidence of 1:10.000, 
PAH deficiency is the most common inborn error of metabolism in Europeans [4]. 
 
 
Figure 1 The basic structure of the human PAH gene. Found on the long arm of chromosome 12 
(12q23.2), the human PAH gene contains 13 exons which encode a polypeptide of 452 amino 
acid [3].
 
 
The PAH is enzyme responsible for the majority of the catabolism of dietary phenylalanine and 
is located mainly in the liver. Phe is derived from dietary protein and turnover of endogenous 
pools. Disposal of Phe is by hydroxylation to Tyrosine (Tyr), incorporation into bound 
(polypeptide) pools, transamination and decarboxylation (Figure 2). At physiological levels, 
hydroxylation to Tyr accounts for 75%, and incorporation into protein for 25% of the total Phe 
disposal. PAH, with tetrahydrobiopterin (BH4), as a cofactor, plus molecular oxygen and iron, 
catalyzes the hydroxylation of Phe to Tyr. Loss of PAH activity, with consequently little or no 
conversion of phenylalanine to tyrosine, results in increased concentrations of phenylalanine in 
the blood and fluids throughout the body and toxic concentrations in the brain [1].  
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The position and nature of the mutation on PAH influence the activity of the PAH enzyme, which 
determines the hyperphenylalaninemia phenotype of the patient. Little or no enzyme activity 
results in the classic phenylketonuria phenotype. Other mutations only partly inhibit enzyme 
activity, giving rise to mild hyperphenylalaninemia or mild phenylketonuria [1]. 
Figure 2.  Phenylalanine metabolism in phenylketonuria. As indicated by the ‘X’, PKU results 
from mutations that affect the hepatic phenylalanine hydroxylase (PAH) enzyme needed for the 
hydroxylation of the indispensable amino acid phe to tyrosine. Due to these mutations which 
reduce the conversion of phe to tyrosine, phe accumulates in blood and is transaminated and 
decarboxylated into many compounds which appear in blood and urine; three of the compounds 
which are measured clinically are shown. Tyrosine, a precursor for multiple biological products, 
becomes an indispensable amino acid (AA) and must be provided by the diet for those with 
PKU. Under physiological conditions, PAH catalyzes about 75% of the phe input from the diet 
and protein catabolism [5].   
 
 
Most severe are individuals with complete enzyme deficiency whose untreated blood Phe levels 
are typically >1200 μmol/L (mean normal level: 60 μmol/l); this phenotype is consistently 
termed “classical PKU.” It should be noted that infants diagnosed and treated earlier in life might 
have a peak PHE level <1200 μmol/L and still have complete PAH deficiency [6]. 
A minority of HPA cases (1-2%) is due to mutation of one of the enzymes involved in the 
synthesis or recycling of PAH genes cofactor, tetrahydrobiopterin (BH4) [7,8].
 
 
Untreated outcomes and pathophysiology  
 
Prognosis and outcome of HPA depend strongly both on the diagnosis and treatment time and on 
the type of mutation. 
1. Introduction. Phenylketonuria and dietary treatment.                   12 
Older children with PKU, if untreated, can show microcephaly, epilepsy, a musty body odour, 
decreased skin and hair pigmentation, eczema, severe intellectual disability and behaviour 
problems as well as structural brain changes visible on magnetic resonance imaging (MRI) [9]. 
Therefore, the major effect of hyperphenylalaninemia in PKU patients is on the brain function 
and development. Although the exact pathophysiologic mechanism by which HPA causes the 
neurocognitive damage is still not completely dissolved, there are several hypotheses supported 
with evidence, which address the different possible causes of the neurotoxicity secondary to 
elevated blood Phe levels: 
 
1) High concentrations of phenylalanine in the blood can inhibit large neutral amino acid 
carrier L-amino acid transporter 1 (LAT1), that mediates the entry of phenylalanine, 
tyrosine and tryptophan into the brain. Because tyrosine is a precursor of dopamine and 
norepinephrine, and tryptophan is a precursor of serotonin, the high concentrations of 
phe, obstructing their entry into the brain, could be the cause of neurotransmitter 
dysfunction and their availability for protein synthesis in PKU patients [8,10]. 
2) Imaging studies have described white matter lesions associated with reduced formation of 
myelin in brain white matter, although no definite causative link between dysmyelination 
and neuropsychological impairment has been established [11,12]. 
3) Other possible mechanisms for hyperphenylalaninemia induced damage to the brain 
include reduced activity of pyruvate kinase, disturbed glutamatergic neurotransmission, 
reduced activity of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, and 
the function of monoamine oxidase B as a modifying gene [13]. 
 
Patients with non-phenylketonuric hyperphenylalaninemia have a lower risk of 
neuropsychological dysfunction than do those with phenylketonuria, although compared with 
healthy controls, some might have decreased executive functioning. Adequate control of blood 
phenylalanine is effective in prevention of most of the central nervous system (CNS) deficits 
associated with phenylketonuria [1]. 
 
Diagnosis 
 
Affected newborns show no clinical signs of hyperphenylalaninemia, so until the introduction of 
the newborn screening, most children born with phenylketonuria became profoundly mentally 
disabled.  Since the '60s, the newborn screening was gradually introduced in several countries, 
starting from the USA and Europe. In Italy, neonatal screening has been required by law since 5 
February1992, but in the Lombardy region has been undertaken since 1 January 1977 [14].  
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Newborn screening is based on the detection of hyperphenylalaninemia in blood spots, as Phe is 
the marker for PAH deficiency. Phe levels in blood spots can be measured by several possible 
methods, but currently tandem mass spectrometry is the routine method of analysis [4]. 
In most cases, after the routine newborn screening test (typically performed 2-7 days after birth, 
using samples drawn by neonatal heel prick), a repeat test is done at approximately two weeks of 
age to verify the initial test and uncover any phenylketonuria that was initially missed. 
Every infant identified in newborn screening with hyperphenylalaninemia should be assessed at 
a metabolic centre as early as possible. If the baby has hyperphenylalaninemia, blood amino acid 
analysis will reveal increased phenylalanine concentrations (>120 μmol/L), normal or reduced 
tyrosine concentrations (phenylalanine to tyrosine ratio >2), and normal concentrations of the 
remaining amino acids [1]. This is the pattern of all forms of hyperphenylalaninemia/ 
phenylketonuria. In these patients two differential diagnostic assessments should be done. First, 
whether or not the patient has a defect in BH4 synthesis or recycling should be clarified. If they 
do not have such defects, whether the patient with hyperphenylalaninemia/ phenylketonuria can 
be treated with diet restrictions only, or can at least be helped in part with BH4 alone or together 
with a restricted diet should be assessed [1]. 
Early diagnosis and prompt intervention have undoubtedly allowed most individuals with 
phenylketonuria show normal overall development, attain expected educational standards, lead 
independent lives as adults, form normal relationships, and obtain employment [15,16]. 
 
Phenotypes 
 
Depending on the enzyme defect, the genotype and the severity of the disease, different forms of 
PKU with different clinical phenotypes have been described. Thus, different classifications for 
PKU phenotypes have been established. PKU may be classified as classic PKU and as variant 
PKU which includes all milder forms of PKU (moderate PKU and mild PKU), as mild HPA or 
non-PKU HPA, and additionally, as BH4-responsive PKU. Definition of PKU phenotypes may 
be essential in establishing treatment options, foe example (e.g.) new therapeutic strategies, in 
counseling and in prediction of the outcome, and in pregnancy. Pre-treatment blood Phe levels, 
the individual Phe tolerance may help to discriminate the different phenotypes of PKU [17]. 
Concerning “mild HPA-gray zone” there is disagreement about the need to treat and there are 
conflicting data on the effects on cognition and executive function, while there is general 
consensus regarding “mild HPA-NT” that no treatment is required [16].  
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Table 1. Phenotypes of PAH deficiency based on blood Phe levels and treatment indication 
(Adapted from [16]). 
PAH deficiency 
 
Pretreatment blood Phe level 
Requiring treatment 
 
 
Classical PKU 
 
>1200 μmol/L 
 
Moderate PKU 
 
900–1200 μmol/L 
 
Mild PKU 
 
600–900 μmol/L 
 
Mild HPA-gray zone 
 
360–600 μmol/L 
Not requiring treatment 
 
 
Mild HPA- NT 
 
120–360 μmol/L 
 
The goal of the treatment is to maintain plasma concentrations of Phe within an acceptable 
range. The acceptable, or target, range for Phe levels varies throughout the world and across ages 
[1]. 
In Italy, the target blood Phe concentration recommended for children under twelve is 120-360 
μmol/L, and for those over twelve it is 120-600 μmol/L. For individuals who are on a low Phe 
diet, it is important to monitor their Phe levels to make sure they are remaining within their target 
zones. The monitoring of blood Phe levels is typically done through blood spot analysis. During 
infancy adjustments to an individual’s diet may need to be assessed weekly, whereas later, 
assessments will not have to occur as close together. 
 
 
1.1.2  Phenylketonuria diet 
 
There is general consensus that the current standard of care and primary treatment for PKU is 
dietary and that this treatment should be continued throughout an individual's lifetime to prevent 
adverse clinical outcomes and cerebral MRI changes, and to promote normal cognitive 
development [16].  
Adherence to the diet is usually straightforward in the neonatal period and during early 
childhood, as the child’s parents control the diet. However, dietary compliance becomes 
increasingly difficult as children approach adolescence due to palatability of the diet. This is 
clearly reflected by poor control of blood phenylalanine concentrations in a proportion of 
individuals in this age group [18].  Dietary restriction of phenylalanine was introduced in 1953 
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by Bickel and colleagues [18]. 
The restriction of dietary Phe usually begins immediately after confirmation of this condition in 
a newborn. During infancy breastfeeding or human milk meals, to provide natural protein 
according to the individual Phe tolerance, and/or a Phe-free infant formula are recommended. 
With the introduction of solid foods, PKU subjects have to avoid foods rich in protein (meat, 
fish, eggs, standard bread, dairy products, nuts and seeds); only in some cases, according to the 
individual Phe tolerance, minimal amounts of animal products (usually milk) are allowed. 
Therefore, PKU diet is mainly made up by low-protein natural foods (vegetables, fruits and some 
cereals), to reach the Phe supply necessary for growing processes. For these reasons, PKU diet 
tends to contain high carbohydrate, low saturated and polyunsaturated fat, cholesterol, iron, zinc, 
selenium and some vitamins (in particular B12) intake, because of the very low assumption of 
Phe-containing animal foods [15].  
 
Phenylalanine exchange systems 
 
There is no standardized method on dietary management of PKU patients.  
A study showed that important differences among centres across Europe in the dietary 
management of PKU and in support systems designed to assist patients in managing their diets, 
exist [19]. 
In some centers patients are instructed with the Phe content of foods, whereas centres, such as in 
Milan, Italy, in Denmark and United Kingdom, lists of food-Phe equivalence in varying 
milligram exchange amounts (10–50 mg Phe exchanges) are released. The idea is that one 
exchange of Phe can easily be swapped for another exchange of equivalent value [19]. In some 
centers (e.g. Norway), patients choose between adherence to a total daily amount of Phe or use 
of an exchange system [19]. 
Some centers (e.g. in Milan, Italy) are opposed to the incorporation of most higher protein foods 
to make up Phe allowance because of the potential for patients to become accustomed to the 
taste, which could lead to a desire for more of it and the consumption of more than the required 
amount, which would thereby reduce compliance [19]. 
The dietary schedules of phenylalanine exchange system are different among PKU centres. 
These schedules are food lists in which is present an exact quantity (e.g. 10 or 20 mg) of Phe for 
a given weight of food.  In the Table 2 are shown examples of the equivalents from vegetables 
and fruits (20 mg of Phe) and the equivalent from grains and milk (10 mg of Phe) used at San 
Paolo Hospital, Milan, Italy. In the list of equivalents from grains and milk are present all low-
protein products commercialized.  In figure 3 is shown an example of diet prescribed to PKU 
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children.  
 
Table 2. Example of Phenylalanine exchange systems. 
EQUIVALENT FROM VEGETABLES 
AND FRUIT  
(1 Equiv. = 20 mg of Phe) 
EQUIVALENT FROM GRAINS AND MILK  
(1 Equiv. = 10 mg of Phe) 
Vegetables g Grains g 
Basil 12 Pasta (Aproten)  33 
Chard 30 Pasta (Harifen) 100 
Broccoli 15 Pasta (Taranis) 80 
Artichokes 15 Lp-Pasta (Milupa) 100 
Carrots 65 Bread “Pane biscottato” (Aproten) 20 
Cauliflower 25 Bread “Ciabatta” (Aprotide) 65 
Cucumber 140 Chocolate Wafer  70 
Green bean  25 Cracker Loprofin 100 
Fennel 25 Cake Mix (Loprofin) 60 
Lettuce  35 Kidbar (Sineamin) 100 
Potato  20 Melba Toast (Aproten) 15 
Tomato 80 Lp-flakes with honey 200 
Spinach 20 Lp-Ringlets 25 
Fruit  Rice 2,5 
Apple 220 Milk  
Kiwi 40 Milco 100 
Grape  60 Whole milk 6 
Pear 85 Whole yogurt   5 
Strawberry 80 Fruit yogurt 4,5 
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DIETA PER: …....   
   
ETA’  :  11 anni   
 
PESO:  46.4 Kg 
 
Alimenti    quantità   Sostituzioni 
 
Colazione 
Latte Milco    250 g                        2 e ½ equiv. di cereali 
Biscotti Aproten     30 g             2 equiv. di cereali  
Zucchero       20 g                       oppure 20 gr di miele o 
marmellata 
X-PHE Junior                  35 g 
 
Spuntino 
Crostini Mevalia                   3 pz (30g)              1 equiv. di cereali 
Pranzo 
Pasta ipoproteica   80 g     1 equiv. di cereali 
Pomodori pelati   60 g     1 equiv. di verdura 
Zucchine     75 g      3 equiv  di verdure 
Carote     65 g     1 equiv. di verdure 
Olio ex. v. di oliva   20 g       
Pesca      55 g      ½ equiv. di frutta 
X-PHE Junior    20 g 
 
Merenda 
Mela               220 g      1  equiv. di frutta 
Pane a fette Mevalia                     3 fette (60g)      1  equiv. di cereali  
 
Cena 
Pasta ipoproteica   80 g     1 equiv. di cereali 
Pomodori pelati   60 g     1 equiv. di verdura 
Zucchine     75 g     3 equiv  di verdure 
Patate      20 g                1 equiv. di verdure 
Olio di oliva    20 g          
X-PHE Junior    20 g 
Figure 3. Example of PKU diet (in Italian). 
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Phenylalanine requirements in PKU 
 
In PKU, the individual dietary phenylalanine tolerance is pragmatically determined and is 
influenced by many factors, such as growth rate, age, gender, compliance, target blood 
phenylalanine concentration. It is defined as the amount of phenylalanine per kg/body weight 
that is tolerated to achieve plasma phenylalanine concentrations within a target range. In PKU, 
generally phenylalanine tolerance/requirements are highest in early infancy (ranging from 55 
mg/kg/day at 0–3 months of age to 27 mg/kg/day at 12 months) [20]. After the age of 1 year, 
there is a slow and steady decline in tolerance per kg/body weight, and even from the early days 
of treating PKU with diet it has been recognized that children with classic PKU, on dietary 
treatment usually only tolerate between 200 and 500 mg/day (0.2–0.5 g daily). Patients with a 
milder form of PKU (untreated blood phenylalanine concentrations less than 1000 μmol/l), 
usually tolerate in excess of 500 mg/day dietary phenylalanine [21].  
Moreover, it is important to highlight that in PKU also tyrosine is an indispensable amino acid, 
because it is not supplied endogenously via phenylalanine hydroxylation or only to a very 
limited degree [21].  
 
Micronutrient status and long-chain polyunsaturated fatty acids in PKU 
 
No tailored micronutrient dietary reference values have been established for PKU, so the optimal 
intake of micronutrients on a low phenylalanine diet is unknown, despite the fact that the 
majority of nutrient sources are chemically derived (European Commission/Scientific Committee 
on Food 1999) [22]. However, clinical studies indicate that any deficiency or nutrient imbalance 
is mainly (but not entirely) due to inadequate dietary intake, and there is little to suggest that 
dietary reference values should vary from the healthy population. Therefore, normal population 
dietary reference values for micronutrients are used as a guideline [23]. However Individual 
polymorphisms and genotype may be important in determining individual nutrient requirement 
[24,25].   
 
• Vitamins  
 
 An absence of meat or fish in the diet without supplementation increases the risk of Vitamin B12 
deficiency, because plant do not not synthesize this vitamin. Therefore, vitamin B12 deficiency is 
mainly reported in adolescents or adult patients who have stopped or relaxed their diets and 
who are less adherent with phe-free L-amino acid supplements [26].  Symptoms such as spastic 
paraparesis, tremor, and slurred speech are associated with deficiency but patients may be 
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unaware of the early manifestations of vitamin B12 deficiency as they appear insidiously. 
In PKU, fractures and reduced bone mineral density have been commonly reported in all age 
groups, but it is unclear if this is due to inadequate mineral, vitamin D, or natural protein intake 
(either due to low intake or poor adherence with phenylalanine-free protein substitute), lack of 
non-essential amino acids such as proline which are abundant in collagen, limited exercise, poor 
blood phenylalanine control or is a consequence of the disorder itself [26]. 
 
• Minerals 
  
The trace mineral status has been widely studied in PKU, but particularly zinc and selenium. 
Concerning zinc status in PKU, there have been conflicting reports. Assessment and 
interpretation of marginal biological zinc deficiency is difficult. There are no reports of clinical 
symptoms of zinc deficiency in PKU but low plasma zinc is still described, despite generous zinc 
supplementation in to phe-free protein substitutes. 
Regarding selenium status, in the early years of PKU treatment, biochemical selenium deficiency 
was common in PKU. The selenium is found predominantly as the amino acid selenomethionine 
(cereal products) and selenocysteine (animal products) and is rich in foods such as Brazil nuts, 
cereals, offal, fish and eggs but low in fruits and vegetables. For this reason, the selenium content 
of a non-supplemented low phenylalanine diet is likely to be low. The majority of selenium in a 
low phenylalanine diet is sourced from added selenium to phe-free protein substitutes [26]. 
 
• Long-chain polyunsaturated fatty acids  
 
Long-chain polyunsaturated fatty acids (LCPUFA) with 20 and 22 carbon atoms are 
metabolically derived from a-linolenic acid (ALA) and linoleic acid (LA) by consecutive 
enzymatic desaturation and chain elongation. Although LCPUFA including DHA (22:6n-3) and 
AA (20:4n-6) can be synthesized from ALA and LA in mammals, respectively, the activity of 
conversion is low in humans [15].  
PKU children who are compliant with the recommended low protein diet are devoid of natural 
dietary sources of n-3 LCPUFA, as LCPUFA rich foods also contain high amounts of protein. 
Accordingly, blood concentrations of n-3 LCPUFA and especially of DHA are reduced in plasma 
and red blood cell phospholipids of PKU children relative to omnivorous children with a more 
marked relative depletion of DHA than arachidonic acid, the major n-6 LCPUFA, throughout 
childhood [15,25,27]. Therefore, given the functional effects, DHA is conditionally essential 
substrates that should be supplied with PKU diet [15]. 
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Phe free protein substitutes and special low protein foods  
 
The required amount of daily proteins is obtained from phe-free protein substitutes providing 
essential amino acids and some micronutrients in suitable proportions [15].  Moreover, low-
protein variants of some foods are commercially present, such as low-protein bread and low-
protein pasta (special low protein foods, SLPF). It would be difficult to achieve acceptable blood 
Phe control without them because they provide an important source of low-phe kilocalories in 
the diet [19]. 
 
Phe free protein substitutes 
 
In PKU, the majority of non-phenylalanine protein is supplied by phe-free amino acids. The 
number of protein substitutes available for PKU patients is increasing constantly with time. The 
absence of Phe is the one constant in these mixtures; but there is variability in the presence or 
absence of lipids, vitamins and minerals with differences also in the amount [15]. Amino acid 
patterns of phe-free amino acids designed for infants, children and adults are primarily based on 
that of human milk [21]. The phe-free protein substitutes for infants meets infants’ requirements; 
most of the different protein substitutes contain DHA and AA and some formulations are 
supplemented with prebiotics. Many products are available with different composition and 
presentation for children, adolescents and adults; this is a great advantage for patients as they can 
choose the product most likely to meet their needs [15]. 
The metabolic and dietary handbooks advise to divide the daily intake of phe-free amino acids 
into at least three equal parts, and to combine the intake of natural protein with the amino acid 
supplement [21]. 
 
 The major progresses in protein substitutes are: 
• Palatability and caloric content: better taste of amino acid powder/lower calories (lipid 
and carbohydrate composition of preparations have been improved); 
• Compliance (all ages): better compliance due to different formulations (powder, tablets, 
creams etc) 
• Age-related problems with diet (childbearing age, adolescence, adult age): different age-
related formulas and composition individualized dietary treatment. Improvements in the 
palatability, presentation, convenience and nutritional composition of substitutes have 
helped to improve long term compliance with PKU diet. Although it can be expected for 
further improvement in this area, PKU patients can choose the product most likely to 
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meet their needs [15,16]. Studies in healthy adults, investigating the bioavailability of 
amino acids mixtures compared to natural protein, demonstrate differences in the rate of 
absorption in the gut. Amino acids delivered as dietary protein (casein) may support 
whole-body protein metabolism better than ingestion of crystalline [21]. 
 
Recently, other than these progresses, a new low phenylalanine whey based protein substitute has 
been developed for PKU, called glycomacroprotein (GMP). It is derived from cheese whey 
(naturally low in phenylalanine) and it is supplemented with valine, isoleucine and threonine. 
Studies suggest that PKU patients find foods containing GMP more palatable than their usual 
amino acid formula, preferring a diet supplemented with GMP. The potential benefits of having 
GMP in the PKU diet have been explored and data showed that the GMP diet significantly 
reduced ureagenesis, improved protein retention and Phe utilization. Another study found that 
consuming the GMP diet for breakfast promoted satiety as reflected by decreased levels of the 
postprandial ghrelin concentration (associated with greater feelings of fullness) when compared 
to an amino acid diet [21]. However, further studies are needed to evaluate the safety and 
efficacy of GMP consumption for long term [18]. 
Studies in healthy adults, investigating the bioavailability of amino acids mixtures compared to 
natural protein, demonstrate differences in the rate of absorption in the gut. Amino acids 
delivered as dietary protein (casein) may support whole-body protein metabolism better than 
ingestion of crystalline L-amino acids, casein hydrolysates or soy protein [21].  
 
Special low protein foods (SLPF) 
 
The function of special low protein foods in the PKU diet is to provide energy and variety in the 
diet.  It is estimated that the patient’s SLPF intake will depend on disorder severity, providing 
around 50% of the total energy intake in the most severe forms of the disorder. Milder 
phenotypes, with a higher natural protein tolerance are likely to be less dependent on their use 
[29].  
SLPF have a low protein and Phe content but their micronutrient composition is unclear. In a 
normal diet, healthy energy food sources commonly provide other macro and micronutrients. In 
direct contrast, SLPF micronutrient fortification is uncommon and it is assumed that the majority 
of vitamins and minerals are provided from L-amino acids supplemented with micronutrients 
[30,31]. 
 SLPF are regulated by the European legislation ‘Foods for Special Medical Purposes’ 
(Commission Directive 1999/21/EC of 25 March 1999; amended in Directive 2006/141/EC). 
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This Directive sets out rules for the composition and labeling of foods that are specifically 
formulated, processed and intended for the dietary management of diseases, disorders or medical 
conditions of individuals who are being treated under medical supervision. The nutritional 
substances that may be used in the manufacture of foods for special medical purposes are also 
outlined in legislation: Commission Regulation (EC) No 953/2009 [32]. In addition, all Foods 
for Special Medical Purposes have to follow the European Food Information to Consumers 
Regulation No 1169/2011 and Regulation No 609/2013 which is only just being enforced in 
many countries. Manufacturers must provide information concerning the energy value and 
principal nutrients contained in such foods but only have to declare the vitamins and/or minerals 
if they are present in “significant amounts”. Seems that in Italy there is the major number of 
SPLF (n = 256) compared with other countries [33].  
A recent study [33] compared Portuguese special low protein foods with corresponding regular 
Portuguese foods: in 75 % of the SLPF subgroups the energy content was higher than in regular 
foods. Moreover, Portuguese SPLF were found higher in lipid (in 58% of SLPF subgroups) and 
carbohydrates (in 92% of SLPF subgroups) content. Another common feature of SLPF is lack of 
label micronutrient information when compared with regular matched-foods. Although 
micronutrients are mainly consumed through L-amino acid supplements [23,26]. SLPF should 
contain a warning indicating that their nutritional profile does not replicate regular foods because 
patients, caregivers and health professionals may assume they provide other nutrients other than 
energy. At present, there are no detailed studies outlining their full nutritional contribution to a 
low Phe diet [33].  
 
In table 3 is shown a comparison between special low protein foods available in Italy with the 
corresponding regular Italian foods. The energy content of low protein foods seemed higher in 2 
(“cookies” and “breakfast cereals”) of the 5 food groups analyzed. Low protein breakfast cereals 
seemed to have a higher soluble sugar intake than regular ones (32.5g vs. 10.4g), and low protein 
breads seemed to have higher fat contents than “regular bread”.  Fiber content of low protein 
foods was higher in 2 (“bread” and “melba toast”) of the 5 food groups analyzed. 
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1.2 Carbohydrate quality 
 
As previously written, PKU diet is characterized by a high carbohydrate intake. For this reason, 
this subchapter deals with this macronutrient and its qualities. 
 
1.2.1 Definition and category of carbohydrates 
 
Chemically, carbohydrates include a range of components such as polyhydroxy aldehydes, 
ketones, alcohols and acids, as well as their derivatives and polymers, e.g. starch and other 
polysaccharides. The chemical classification of carbohydrates is usually based on molecular 
dimensions and monomeric composition, three principal groups being sugars (1–2 monomers), 
oligosaccharides (3–9 monomers) and polysaccharides (10 or more monomers) [1]. 
From nutritional point of view, it is important to differentiate between two broad categories of 
carbohydrates: those digested and absorbed in the human small intestine, providing 
carbohydrates to body cells and those passing to the large intestine, forming substrate for the 
colonic microflora [2]. A FAO/WHO Expert Consultation on Carbohydrates in Human Nutrition 
[1] recommended the introduction of the concept ″glycemic carbohydrate″, meaning providing 
carbohydrate for metabolism, which corresponds to the previously used term ″available 
carbohydrates″ and to ‶carbohydrates″ according to the European legislation. The nondigestible 
(unavailable) carbohydrates are commonly referred to as ‶dietary fiber″ [1,3]. 
 
Table 4. The main types of dietary carbohydrates [3]. 
Class (DPa) Subgroup Principal components 
 
Sugars (1-2) Monosaccharides 
Disaccharides 
 
Polyols (sugar alcohols)  
Glucose, fructose, galactose 
Sucrose, lactose, maltose, trehalose 
 
Sorbitol, mannitol, lactitol, xylitol, 
erythritol, isomalt, maltitol 
Oligosaccharides (3-9) / 
short-chain carbohydrates 
Malto-oligosaccharides  
(α-glucans) 
Non- α-glucan 
oligosaccharides 
Maltodextrins 
 
Raffinose, stachyose, fructo and 
galacto oligosaccharides, 
polydextrose, inulin 
Polysaccharides (≥10) Starch (α-glucans) 
 
Non-starch 
polysaccharides (NSPs) 
Amylose, amylopectin, modified 
starches 
Cellulose, hemicellulose, pectin, 
arabinoxylans,  
β-glucan, glucomannans, plant 
gums and mucilages, hydrocolloids 
aDegree of polymerization or number of monomeric (single sugar) units. 
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1.2.2 Glycemic carbohydrates: metabolism  
 
The glycemic carbohydrates provide carbohydrate to body cells, mainly in the form of glucose. 
The main glycemic carbohydrates are: glucose and fructose (monosaccharides), sucrose and 
lactose (disaccharides), malto-oligosaccharides, starch (polysaccharide). In general, only 
monosaccharides are absorbed in the small intestine. The enzymatic degradation of starch begins 
by the action of salivary amylase and is continued in the small intestine by pancreatic amylase. 
The degradation products – mainly maltose and oligosaccharides – are hydrolysed further to 
glucose by a set of enzymes ‶disaccharidases″, bound to the brush border membrane of the 
enterocytes. The same enzymes hydrolyse the dietary disaccharides. Glucose and galactose are 
absorbed efficiently by a secondary active carrier coupled with sodium (sodium glucose 
transporter 1, SGLT1), whereas fructose is absorbed by facilitated diffusion that does not involve 
sodium co-transport (GLUT5). The absorption of monosaccharides is regarded as the rate-
limiting step. Absorbed monosaccharides are transported to the liver and then to the systemic 
circulation. The cellular uptake is mediated by a number of glucose transporters (GLUT1–4), 
variously expressed in different tissues. Insulin is a key hormone for the uptake and metabolism 
of glucose. The plasma insulin concentration increases immediately after ingestion of glycemic 
carbohydrates. Unlike glucose, fructose enters body cells without the need for insulin. The 
metabolism of fructose, therefore, favours lipogenesis more than glucose. In liver cells, fructose 
is phosphorylated to fructose-1-phosphate that can be converted to fatty acids, providing a route 
for lipogenesis in addition to that shared with glucose (via glucose/fructose-6-phosphate). Both 
fructose and galactose, the latter arising from hydrolysis of lactose, are also transformed to 
glucose mainly in the liver [1]. 
 
1.2.3 Glycemic index (GI) and glycemic load (GL)  
 
The concept of glycemic index (GI) was introduced by Jenkins and co-workers in 1981, in order 
to rank foods in a standardized way according to their effects on blood glucose levels after a 
meal [4]. The FAO/WHO Expert Consultation defined GI as the incremental area under the 
blood glucose response curve during 1.5–3 hours after intake of a 50 g carbohydrate portion of a 
test food (usually glucose or white bread), and expressed as a percentage of the response to the 
same amount of carbohydrate from a standard food taken by the same subject [5].  
Foods having carbohydrate that is digested, absorbed and metabolized quickly are considered 
high GI foods (GI ≥ 70 on the glucose scale) whereas those that are digested, absorbed and 
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metabolized slowly are considered low GI foods (GI ≤ 55 on the glucose scale) [6].  
Glucose or white bread is used as standard. GI values obtained with the white bread standard are 
typically about 40% higher than those obtained with the glucose standard which is the generally 
preferred standard. GI values for about 750 foods have been published [7] and updated with 
additional data to contain 2480 individual food items [8]. Recently, in Italy, Scazzina et al. 
published GI values of 141 Italian commercial foods [9]. Whereas it was previously assumed 
that sugars are rapidly absorbed and therefore have a higher GI than polysaccharides (e.g. 
starch), which are slowly absorbed, a number of food-related factors have been identified to 
determine the GI: fructose has a low GI (30 with the white bread reference as 100) and sucrose 
an intermediate GI (lower than white bread) [10]. Starchy foods, on the other hand, can have low, 
intermediate or high GI, depending on their composition (amylose/amylopectin ratio) and 
physical/chemical state. The swelling and dissolution of starch at wet heat treatment, known as 
gelatinization, is particularly important in making starch more readily accessible to digestive 
enzymes. Physical barriers such as in intact cereal grains, cellular structures in leguminous seeds, 
parboiled rice and whole fruits, and the protein network in pasta products, are food-related 
factors lowering the GI. Organic acids (acetic, propionic and lactic acid) decrease the glycemic 
response to foods or meals, mainly due to inhibition of gastric emptying [11]. Viscous, soluble 
types of dietary fiber may also delay gastric emptying, in addition to their inhibitory effect on 
diffusion and transport in the small intestine [12]. 
In practice, the blood glucose response after a meal is influenced by both the GI and the amount 
of carbohydrate in a portion of a food. Consequently, the glycemic load (GL) concept was 
introduced in 1997 to quantify the glycemic effect of a portion of food [13]. GL is defined as the 
mathematical product of the grams of available carbohydrate in the food portion and the food’s 
GI, divided by 100, and the sum of singular GL values for foods and meals has been used to 
estimate the glycemic load of the whole diet. 
Studies have shown that the glycemic response to a meal can be predicted from properly 
determined GI of the constituent foods. However, the glycemic response can also be influenced 
by the protein and fat content, and by the type and amount of beverage taken with the food [14]. 
 
1.2.4 Factors influencing the blood glucose responses of foods 
 
Factors affecting the rate of glucose absorption from starchy food and therefore the GI value 
include: 1) the nature of the food and 2) the type and extent of food processing (Table 5). The 
former includes the ratio of amylose to amylopectin present in the raw food and the type of 
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monosaccharide components, the amount and type of dietary fiber, the presence of large amounts 
of fat or protein, antinutrients such as phytic acid, lectins and tannins and nutrient – starch 
interactions in carbohydrate-containing foods, such as in wheat products. Extrusion, flaking, 
grinding, canning, storing and cooking of the carbohydrate-containing foods can affect the 
particle size and the integrity of the starch granules and plant cell walls, making the carbohydrate 
portion more accessible to digestive enzymes. Fat and protein may modify the glycemic response 
to a carbohydrate food by slowing gastric emptying and increasing insulin secretion, respectively 
[15]. 
 
Table 5. Factors that influence the glycemic response and the glycemic index. 
Factors that affect GI  
 
Factors that decrease GI Factors that increase GI 
Nature of starch ↑ Amylose/amylopectin ↓ Amylose/ amylopectin 
Nature of monosaccharide 
components 
Fructose 
Galactose 
Glucose 
Viscus fiber ↑ Guar 
↑ β-glucan 
↓ Guar 
↓ β-glucan 
Cooking/food processing Parboiling 
Cold extrusion 
Extruding 
Flaking 
Popping 
Particle size Large particles Grinding (small particles) 
Ripeness and food storage Unripeness 
Cooling 
Ripeness 
α-Amylase inhibitors ↑ Lectins 
↑ Phytates 
↓ Lectins 
↓ Phytates 
Nutrient starch interactions ↑ Protein 
↑ Fat 
↓ Protein 
↓ Fat 
↑=high levels. 
↓=low levels. 
  
 
 
1.2.5 GI/GL during childhood and its relevance for metabolic outcomes 
 
Growing evidence underscores the important role of glycemic control in health and recovery 
from illness [16]. Carbohydrate quality and digestibility can influence post-prandial plasma 
glucose concentration and the inflammatory response, which is now known to underlie the 
development of insulin resistance, metabolic syndrome, and type 2 diabetes mellitus (T2DM). 
Foods with high GI and GL are associated with increased risk of such diseases [16]. Conversely, 
lowering dietary GI and GL can improve metabolic control [16]. 
Recent use of meta-analytical methods has been illuminating in understanding the role of GI/GL 
in the development and management of some diseases, such as diabetes mellitus type 2 and 
cardiovascular diseases [6]. To date meta-analyses indicate, as for T2DM, a stronger beneficial 
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relation between CHD and lower GI/GL in non-diabetic women more than in men among 
prospective cohort studies [17-19]. Reasons for difference between men and women in respect of 
both incident T2DM and incident CHD remain to be elucidated [6].  
Evidence on the relevance of GI/GL for risk markers of Diabetes Mellitus type 2 and CVD in 
children and adolescents is still emerging. Smaller intervention studies suggest some benefits of 
low GI/GL diets specifically for insulin resistance [20-22]. However, in a recent 2-year 
intervention on 113 obese hispanic children the examined diets did not differ in their effect on 
changes in insulin resistance or markers of the metabolic syndrome [23]. Similarly, in a sub-
sample of 253 children and adolescents participating in the DiOGenes study, dietary GI did not 
affect cardiovascular risk markers [24]. Conversely, prospective cohort studies suggest long-term 
adverse health consequences of a habitually higher GI or GL during adolescence. In an 
Australian adolescent cohort, increases in dietary GI and GL between age 12 and 17 years were 
related to substantial concurrent increases in systolic blood pressure among 278 girls [25]. 
Consideration of the GI in the diet of children and adolescents is of long-term relevance, since 
nutritional behaviors are shaped during childhood and adolescence. Of note, analysis of dietary 
GI in a representative sample of Australian children and adolescents revealed that a preferred 
selection of carbohydrates from low GI sources may indeed confer benefits for overall nutrient 
adequacy [26]. By contrast, adherence to the current recommendations to increase whole grain 
consumption and/or reduce intake of sugary foods cannot be expected to translate into a lower 
dietary GI/GL. Associations of dietary GI to dietary fiber are neither strong nor uniform across 
pediatric populations [27,28].  
To confirm this, in the DONALD cohort, 76% of the whole grains consumed by healthy 
adolescents came from sources with higher dietary GI (GI ≥55) [29] which reflect the fact that 
many whole grain products have a relatively high GI [8]. 
 Also, contrary to the popular belief a higher dietary sugar intake is not related to a higher dietary 
GI because all common sugars, except glucose, are of moderate (sucrose) or low GI (fructose 
and lactose) [8,30].  
Since dietary GI is not closely related to dietary fiber or dietary sugar intake it needs to be 
addressed as a separate entity in nutritional recommendations given to children and adolescents. 
Efforts to reduce the dietary GI and GL in children and adolescents should best be targeted to 
energy-dense starchy food, since these make a considerable contribution to total dietary GL in 
children and adolescents [28]. 
In conclusion, a recent International Scientific Consensus Summit from the International 
Carbohydrate Quality Consortium (ICQC) [6], showed that there is convincing evidence that 
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diets low in GI reduce the risk of type 2 diabetes, improve glycemic control in people with type 2 
and type 1 diabetes and reduce the risk of coronary heart disease, meanwhile probable evidence 
has emerged for low GI/GL diets in reducing total body fat mass and in weight management. 
Therefore, the consensus recommended that foods low in GI and GL should be considered in the 
context of a healthy diet [6].
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Abstract Aims: The aim of this paper is to review the possible relationship of restricted phenyl-
alanine (Phe) diet, a diet primarily comprising low-protein foods and Phe-free protein substi-
tutes, with major cardiovascular risk factors (overweight/obesity, blood lipid proﬁle, plasma
levels of homocysteine, adiponectin and free asymmetric dimethylarginine (ADMA), oxidative
stress and blood pressure) in PKU children.
Data synthesis: In PKU children compliant with diet, blood total cholesterol, low-density lipopro-
tein cholesterol (LDL-C), plasma ADMA levels and diastolic pressure were reported to be lower
and plasma adiponectin levels to be higher compared to healthy controls. No difference was
observed in overweight prevalence and in high-density lipoprotein cholesterol (HDL-C) levels.
Inconsistent results were found for plasma homocysteine levels and antioxidant status.
Conclusions: PKU children compliant with diet seem to display non-different cardiovascular risks
compared with the healthy population. Well-designed longitudinal studies are required to clarify
the potential underlying mechanisms associated with PKU and cardiovascular risk factors.
ª 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.
Introduction
Phenylketonuria (PKU; OMIM 261 600) is an autosomal
recessive disorder of phenylalanine (Phe) metabolism [1],
primarily due to mutations in Phe hydroxylase (PAH) gene,
which facilitates conversion of the essential amino acid
Phe to tyrosine. Loss of PAH activity results in increased
Phe concentrations in the blood (hyperphenylalaninaemia,
HPA) and therefore in toxic concentrations in the brain.
Various combinations of mutations [2] result in a full
spectrum of metabolic phenotypes ranging from severe,
moderate and mild PKU (blood Phe concentration
>360 mmol/L), which require dietary management, to mild
HPA (blood Phe concentration: 120e360 mmol/L), wherein
dietary restriction is not necessary [3]. A minority of HPA
Abbreviations: ADMA, asymmetric dimethylarginine; BH4, tetra-
hydrobiopterin; BMI, body mass index; CVD, cardiovascular dis-
ease; HDL-C, high-density lipoprotein cholesterol; HPA,
hyperphenylalaninaemia; LDL-C, low-density lipoprotein choles-
terol; NO, nitric oxide; PAH, phenylalanine hydroxylase; Phe,
phenylalanine; PKU, phenylketonuria.
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1.3 Cardiovascular disease risk factors in PKU children on dietary treatment
cases (1e2%) are due to mutation of one of the enzymes
involved in the synthesis or recycling of PAH gene cofactor,
tetrahydrobiopterin (BH4) [4,5].
In developed countries, PKU subjects are identiﬁed at
birth through newborn screening programmes and clas-
siﬁed by their clinical phenotype. The minimum pre-
treatment Phe levels, requiring a Phe-restricted diet, vary
among different countries [6]. Differential diagnosis be-
tween the two major forms of HPA (PAH or BH4 deﬁ-
ciency) is performed by BH4 loading test, analysis of
urinary pterins, determination of dihydropteridine reduc-
tase activity in blood, analysis of pterins, folates and
neurotransmitter metabolites in cerebrospinal ﬂuid and
enzyme activity measurement.
High blood Phe levels are neurotoxic mainly because of
their inhibitory effect on the bloodebrain barrier transport
of free L-amino acids (leucine, isoleucine, valine, tyrosine,
tryptophan and lysine) that are necessary for the synthesis
of proteins and neurotransmitters (dopamine and seroto-
nin) [3,5]. PKU children, if untreated, can exhibit micro-
cephaly, epilepsy, a musty body odour, decreased skin and
hair pigmentation, eczema, severe intellectual disability
and behaviour problems as well as structural brain
changes visible on magnetic resonance imaging [7]. Prog-
nosis and outcome depend on both time of diagnosis and
type of mutation [8].
Despite the new advancements and treatment strate-
gies (e.g. large neutral amino acids, BH4, gene therapy, Phe
ammonia lyase), dietary intervention remains the main-
stay of PKU therapy [8].
PKU: dietary treatment
The main treatment for PKU is an early Phe-restricted diet,
which aims at reducing blood Phe to non-toxic levels [8].
During infancy, breastfeeding is recommended to provide
natural proteins according to the individual Phe tolerance,
and/or whether necessary a Phe-free infant formula is
used. With the introduction of solid foods, PKU infants
have to avoid foods rich in protein (meat, ﬁsh, eggs, dairy
products, standard bread, nuts and seeds). Therefore, PKU
diet mainly comprises low-protein natural foods (vegeta-
bles, fruits and some cereals), to reach the ideal Phe levels
necessary for growth processes. The allowed intake of low-
protein natural foods is commonly calculated on the basis
of their Phe content. Nowadays, low-protein variants of
some foods are commercially present, such as low-protein
bread and low-protein pasta [9]. The overall required
amount of daily protein intake is obtained consuming
additional Phe-free protein substitutes that supply essen-
tial amino acids in suitable proportions [3,8].
This type of dietary regimen usually includes high car-
bohydrate content, low saturated and long-chain poly-
unsaturated fat, cholesterol, carnitine, taurine, iron, zinc,
selenium, calcium, folates, A, C, D, E and B2, B6, B12 vita-
mins, because of the very low consumption of Phe-
containing animal foods [8,10,11]. Indeed, a study
observed that PKU children compliant with diet
consumed < 7% of saturated fats including <50 mg
cholesterol per day [12]. Moreover, PKU subjects must rely
on the endogenous synthesis of long-chain poly-
unsaturated fatty acids from their precursors; the content
of these acids is often suboptimal in dietary products for
patients with PKU, particularly of a-linolenic acid, pre-
cursor of docosahexaenoic acid [8,10,13]. These character-
istics of the diet for subjects with PKU may resemble those
of a vegan diet with respect to the composition of
permitted natural foods. Vegan diet has been recently
considered within healthy populations for the presumed
health beneﬁts, including potential effects on cardiovas-
cular health [14]. However, consumption of some foods of
the usual vegan diet, rich in micronutrients (cereals, nuts,
etc.), is restricted in PKU subjects because of their high
protein content. PKU subjects need therefore nutritional
supplements (by Phe-free protein substitutes or given
separately) to meet the dietary reference intakes for
micronutrients. Besides, it is worth noting that patients
with severe PKU are provided with a signiﬁcantly high
percentage of dietary supplements such as folic acid and
vitamin B12 [15e17].
Overall, while there is a general agreement that PKU
patients need long-term dietary counselling and daily
nutritional supplementation [8], particular attention
should be paid concerning the micronutrient intake [17].
Cardiovascular disease
Cardiovascular disease (CVD) remains to be the major
cause of deaths worldwide. More than 3 million of these
deaths occurred before the age of 60, which could have
largely been prevented. The percentage of premature
deaths from CVD ranges from 4% in high-income countries
to 42% in low-income countries [18].
The burden of disease will increase with an ageing
population and increasing levels of obesity and sedentary
lifestyles [18]. Diet has long been implicated in managing
and reducing the risk of CVD [19]. The assessment of CVD
risk factors relies mainly on the evaluation of dietary
habits, anthropometric measurements, blood lipid proﬁle,
homocysteine and inﬂammatory biomarker levels, blood
pressure as well as genetic and psychosocial factors [20].
Topic of review
This paper reviews the literature published over the past
15 years and discusses the potential relationship of
restricted Phe diet in PKU children with cardiovascular risk
factors (overweight/obesity; blood lipid proﬁle; plasma
levels of homocysteine, adiponectin and free asymmetric
dimethylarginine (ADMA); oxidative stress; and blood
pressure).
Methodology
Publications were identiﬁed from a PubMed search using
the terms ‘obesity’, ‘overweight’, ‘lipid proﬁle’, ‘choles-
terol’, ‘long-chain polyunsaturated fatty acids’, ‘homocys-
teine’, ‘micronutrients’, ‘adiponectin’, ‘asymmetric
dimethylarginine’, ‘nitric oxide’, ‘oxidative stress’, ‘blood
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pressure’ and ‘phenylketonuria’ and ‘PKU diet’. Other
publications came from the reference list of other papers,
hand searches and from the personal reference databases
of the authors.
CVD risk factors in PKU children on dietary treatment
Overweight/obesity
Obesity is strongly related to major cardiovascular risk
factors, and its impact on CVD is well recognized [18,21].
A recent review [22] regarding overweight issue in PKU
summarized that the earliest studies described a tendency
for overweight in PKU, but the results are inconsistent,
although an increasing number of studies described higher
obesity prevalence in female PKU patients than healthy
controls. A study, included in the review, demonstrated
that in PKU children compliant with diet, the prevalence of
overweight at 8 years of age (25%) was comparable to the
values estimated in normal populations [23]. Similarly,
another study found no statistically signiﬁcant differences
regarding the prevalence of overweight and obesity be-
tween PKU children (<10 years) and healthy controls (25%
vs. 15.4%, respectively) [24]. In the same study, a higher
prevalence of overweight and obesity was observed in PKU
subjects (3e30 years) with poor metabolic control than in
those with good metabolic control (42.9% vs. 27.9%,
respectively) [24]. Moreover, Burrage et al. observed an
overall overweight rate of 40% in PKU subjects (2e20
years) with sex difference (males 27% vs. females 55%)
[25].
Following the review by Rocha et al. [22], other two
studies were published investigating the risk of obesity in
PKU [26,27]. The ﬁrst study performed on 54 PKU patients,
followed up from birth up to 18 years, found weight and
body mass index (BMI) slightly higher in PKU patients
compared to the reference population, but without
reaching statistical signiﬁcance [26]. The second is a
retrospective longitudinal study evaluating the anthropo-
metric characteristics of the PKU subjects collected every 6
months from birth to 18 years of age [27]. In this study, the
prevalence of obesity was higher in PKU children than in
general population, from 8 years of age, without sex dif-
ference [27].
In healthy population, an early age at adiposity rebound
(age at the nadir of BMI) has been additionally suggested
as a predictor of both higher BMI during adolescence and
adult age and late onset of overweight [28]. Similarly, PKU
children overweight at 8 and 18 years of age showed
earlier adiposity rebound than non-overweight PKU chil-
dren [23,27].
Although not signiﬁcantly accurate, BMI is the most
common surrogate measure of adiposity in children and
adults [29]. A study did not ﬁnd differences between
paediatric PKU subjects (<19 years of age) and healthy
control regarding fat and fat-free mass, using a single-
frequency bioelectrical impedance analyzer [30]. Another
study did not ﬁnd differences in body composition
(measured from bioelectrical impedance and skinfold
thickness) between the PKU children (8 months to 7 years)
and French reference population [31]. Conversely, a study
evaluating the body composition using the BOD POD
whole-body air displacement plethysmography method
found that PKU children had a higher body fat percentage
than healthy controls although BMI values in the two
groups were similar [32]. In this study, no association was
observed between the mean blood Phe levels and body fat
percentage in PKU children [32].
Some factors could inﬂuence the tendency towards
obesity, as reported in some studies, in PKU population.
Probably the greater weight gain of PKU patients may be
related to the intake of protein substitute having a high
energy content [33]. In particular, from 10 years of age
onwards, PKU patients may have less supervision from
parents regarding consumption of Phe-free protein sub-
stitutes and meal preparation and consequently a higher
energy intake [25]. Furthermore, it has been suggested that
increased BMI observed in PKU subjects could be related to
the avoidance of sporting activities due to the reported
social isolation and anxiety of these patients [33]. Physical
inactivity is an important modiﬁable risk factor in the
development of CVD [34]. However, nowadays, no pub-
lished paper evaluated the physical activity in PKU children.
In conclusion, the majority of evaluated studies found that
the prevalence of overweight/obesity in PKU population
with good dietary compliancewas not different from that of
the general healthy population. Further studies are needed
to conﬁrm these data and to clarify the possible nutritional
and lifestyle habit factors associated with overweight/
obesity in the PKU population compliant with diet.
Blood lipid proﬁle
The alteration of blood lipid proﬁle is a metabolic risk
factor that plays a key role in the aetiology of atheroscle-
rosis, one of the major underlying pathological processes
that lead to heart attacks and strokes [18]. Indeed, low-
density lipoprotein cholesterol (LDL-C) is deposited in
the walls of arteries and causes atherosclerosis. In addi-
tion, triglycerides increase the risk of atherosclerotic CVD.
By contrast, high-density lipoprotein cholesterol (HDL-C)
protects against vascular disease by removing the LDL-C
from the walls of arteries and thus reducing the risk of
atherosclerosis [18]. A healthy diet can contribute to a
desirable blood lipid proﬁle [18].
The reduction in the intake of animal lipids and
cholesterol, a major feature of PKU diet, could be deﬁned
as a non-atherogenic diet [35]. The blood lipid proﬁle of
PKU children with good metabolic control has been
analyzed in few studies [12,35e38]. In some studies, PKU
children on diet exhibited lower cholesterol levels
compared to the healthy controls [35,37,38]. However, a
study showed that the cholesterol levels did not differ
between PKU and healthy children [36].
Lower LDL-C levels were observed in PKU children on
dietary treatment than in the healthy controls [35,37,38].
However, this difference was not found in another study
[36].
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The majority of the evaluated studies did not show
differences between PKU children and controls for plasma
HDL-C [35e38] and triglyceride levels [37,38]. However, a
study demonstrated that the triglyceride levels were
higher in PKU children with a good metabolic control
compared to the healthy group [36].
LDL-C particle size is another relevant factor involved in
the pathogenesis of CVD. High LDL-C/apolipoprotein B
(Apo B, the almost exclusive apolipoprotein of LDL
cholesterol) ratio is associated with the presence of larger
and less atherogenic particles that are less susceptible to
oxidative damage than small LDL particles [35]. The LDL
particles size could be related to PKU diet. Indeed, a study
observed that LDL-C/Apo B ratio was higher in the group of
PKU children compliant with diet than in non-compliant
PKU and healthy controls [35]. Larger and less athero-
genic LDL particles were associated with a high Zn/Cu ratio
in PKU children compliant with diet [35]. These data could
suggest that some minerals may play an important role in
the lipoprotein metabolism in patients with PKU on diet;
they are involved in the metabolic activities and also are
associated with the size of LDL particles. The PKU patients,
strictly adhering to diet, may be not at risk of developing
atherosclerosis as their blood lipid proﬁle may be less
atherogenic as compared to PKU not adhering to dietary
treatment and healthy controls [35].
Finally, it is important to highlight that genetics may
inﬂuence the response to diet. Indeed, genetic variations in
Apo B may play a major role in modifying the response to
diet and its fat composition [12]. A study performed on
PKU children compliant with diet found that the Apo B
XbaI polymorphism (X-) may be associated with a
favourable response to long-lasting diets low in total fats,
saturated fats and cholesterol [12].
In conclusion, results from literature suggest similar or
better lipid proﬁle in PKU children than healthy controls.
Plasma homocysteine level
Homocysteine, a sulphur-containing amino acid, is recy-
cled into methionine by a transmethylation reaction
requiring folate and vitamin B12. Folic acid and vitamin
B12 and B6 deﬁciencies and reduced enzyme activities
inhibit the breakdown of homocysteine, thus increasing
the intracellular homocysteine concentration [39]. Plasma
homocysteine levels are associated with the risk of CVD
[39]. Some of the supposed mechanisms include an in-
crease in proliferation of vascular smooth muscle cells,
endothelial dysfunction, oxidative damage, an increased
synthesis of collagen and deterioration of arterial wall
elastic material [39].
Six studies evaluated the homocysteine levels in PKU
children on dietary treatment [20,37,38,40e42]. Stolen
et al. [42] showed that 68% of 34 PKU children on dietary
treatment had plasma homocysteine concentrations below
the reference range. In this study, 91% and 53% of the
studied children had plasma folate and vitamin B12 levels
above the upper reference level, respectively [42]. Simi-
larly, Huemer et al. reported lower plasma homocysteine
concentrations in 16 treated PKU children and adolescents
than the age-matched controls [40]. No difference was
found for folate levels [40]. However, in another study, no
difference was observed in the homocysteine concentra-
tions in PKU subjects (age: 4e20 years) on dietary treat-
ment and in controls, although the folate and vitamin B12
levels were higher in PKU subjects [41]. Furthermore,
Karam et al., [20] recently, showed no difference in the
homocysteine levels between nine patients with PKU
(eight children and one adult) and control group (30
healthy subjects, mean age: 12.1 years). On the contrary,
Schulpis et al. found homocysteine concentrations twice
higher in PKU children compliant with diet than in non-
compliant PKU and in healthy controls [37,38]. Moreover,
the PKU subjects compliant with diet showed a lower di-
etary intake of folate and vitamin B12 than the healthy
controls [37,38].
In conclusion, the available studies on homocysteine
concentrations in PKU children on dietary treatment
found inconsistent results. Further studies are needed to
understand the relationship between PKU diet and ho-
mocysteine levels taking into account that PKU children
use Phe-free protein substitutes enriched with folate and
vitamin B12 [15e17]. However, it should be noted that not
all studies speciﬁed dietary compliance of PKU subjects,
the folate and vitamin B12 levels in the Phe-free protein
substitutes and the impact of genetic polymorphisms on
plasma homocysteine levels.
Plasma adiponectin level
Adiponectin, an adipose tissue-derived hormone, pre-
vents endothelial inﬂammation and early atherogenesis
[43]. It seems to exhibit protective functions in an
experimental model of vascular injury suppressing the
attachment of monocytes/macrophages to endothelial
cells, a fundamental early step in the atherosclerotic
process [43]. Moreover, expression of this protein de-
creases with an increase in adiposity, and it also has an
insulin-sensitizing effect mediated through binding to its
receptors AdipoR1 and AdipoR2, thereby leading to the
activation of different signalling pathways [44]. The study
conducted by Schulpis et al. [37] showed that PKU chil-
dren compliant with diet had higher plasma adiponectin
levels compared to the healthy children. Interestingly PKU
children not compliant with diet showed elevated adi-
ponectin concentrations compared to those compliant
with diet and the healthy controls [37]. The authors
suggested that the increased adiponectin levels in non-
compliant PKU patients might be due to the decreased
inhibition by low concentrations of catecholamines,
directly acting on adiponectin production and/or release
in blood stream [37].
To our knowledge, this is the only study evaluating
adiponectin concentrations in a population of PKU sub-
jects. Further studies must be conducted to evaluate the
existence of a possible relationship between PKU diet, di-
etary compliance and adiponectin levels for more scientiﬁc
evidence.
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Plasma-free asymmetric dimethylarginine level
There is growing interest in the nutritional factors modu-
lating endothelial functions [45]. Free asymmetric dime-
thylarginine is a competitive inhibitor of nitric oxide (NO)
synthases. NO is a potent vasodilatator, protects functional
integrity of the endothelium and inhibits platelet aggre-
gation. Therefore, suppression of NO synthesis is a risk
factor for atherosclerosis [40]. In adults, an increase in
plasma ADMA concentrations by 0.1 mmol/L results in an
odds ratio of 2.61 for coronary heart disease [40]. However,
in oxidative stress conditions, NO synthase inhibition by
ADMA may exert protective effects [40,46]. The assess-
ment of ADMA concentrations in PKU subjects could be
justiﬁed considering that ADMA, synthesized by dime-
thylation of protein-bound L-arginine residues and
consecutive degradation of these proteins, might be higher
in PKU subjects than controls due to altered protein
metabolism induced by PKU diet, containing large
amounts of synthetic amino acids [40].
A cross-sectional study [40] investigated plasma-free
ADMA concentrations in 16 PKU children (mean age: 10
years) on dietary treatment and 91 healthy controls. This
study found that in contrast to the hypothesis, PKU chil-
dren had lower ADMA concentrations compared to con-
trols [40]. This result was conﬁrmed also by another
study [45].
Although the literature is scarce, a lower ADMA plasma
concentration was found in PKU subjects on strict diet
than in the control group. However, further investigations
are needed to elucidate the role of PKU diet in ADMA
concentrations.
Oxidative stress
Oxidative stress is involved in the development of many
diseases, such as atherosclerosis, heart failure and
myocardial infarction [47]. Oxidative stress is an imbalance
between the systemic manifestation of reactive oxygen
species and the ability of the biological system to readily
detoxify the reactive intermediates or repair the resulting
damage [47]. Modiﬁcations in the normal redox state of
cells can cause toxic effects through the production of
peroxides and free radicals, thus damaging all cellular
components [47]. Altered antioxidant capacity is observed
in PKU, both in human and animal models, and markers of
lipid, protein and DNA damage have been shown to sug-
gest an increased production of reactive species in this
disease, probably due to the depletion of antioxidant
micronutrients [16].
The PKU diet includes good sources of dietary antioxi-
dants (phytochemicals, some vitamins and minerals), but
it could be a risk factor for some micronutrient deﬁciencies
(selenium, zinc, ubiquinone-10 and L-carnitine) unless
supplemented [48,49]. PKU children compliant with diet
showed a signiﬁcant elevation of b-carotene and a-
tocopherol intake as well as in blood concentrations
compared to those not compliant with diet and healthy
children [50]. These high levels of antioxidants probably
may contribute to increased antioxidant status [50]. In a
more recent study, total antioxidant status was higher in
PKU children on strict diet than in those on loose diet, with
no difference between PKU on strict diet and controls [51].
In conclusion, evaluated studies found that PKU chil-
dren compliant with diet may have a “better antioxidant
status” than not accurately compliant children. Results
evaluating the antioxidant status of PKU children than
healthy controls were inconsistent.
Blood pressure
Some long-term cohort studies have shown that hyper-
tension in adolescence or young adulthood is strongly
related to later risk of stroke or coronary heart disease,
independent of blood pressure in mid-life [52]. Two
studies evaluated the blood pressure of PKU subjects (both
adults and children) on dietary treatment compared to
age-matched controls. Rocha et al. [24] observed a lower
diastolic and systolic blood pressure in PKU subjects than
controls (48 vs. 52 mmHg and 104 vs. 110 mmHg,
respectively). Huemer et al. [40] showed that children with
PKU on dietary treatment had a lower diastolic pressure
than controls (64 mmHg vs. 66 mmHg; p < 0.0001)
without any difference in systolic pressure (108 mmHg vs.
117 mmHg) [40].
In conclusion, few studies have been conducted in PKU
subjects about this cardiovascular risk factor. These data
do not allow us to draw a conclusion about a possible
protective effect of PKU diet on blood pressure.
Results and discussion
A summary of the major conclusions from this review is
presented in Table 1. These are based on the possible as-
sociation of restricted Phe diet in PKU children with main
cardiovascular risk factors.
Out of the evaluated literature [23,24,26], no difference
between PKU compliant with diet and healthy population
was observed for overweight/obesity prevalence while
only a study found higher prevalence of obesity in PKU
subjects aged 8e18 years [27]. PKU children showed lower
diastolic pressure than healthy controls [24,40], but the
observed values were within the reference range both in
PKU and healthy children. Concerning blood lipid proﬁle,
PKU children showed lower total cholesterol and LDL-C
[35,37,38] levels than healthy controls, but no difference
was observed for HDL-C levels [35e38]. Although the
observed lower levels of LDL-C suggest a better lipid pro-
ﬁle, a recent review highlighted that non-HDL-C is a better
predictive indicator of CVD in children [53]. Unfortunately,
there are no studies currently evaluating non-HDL-C levels
in PKU subjects. Only a caseecontrol study assessed adi-
ponectin levels in PKU children and found higher levels in
PKU than healthy controls. The protective effects of higher
adiponectin levels against CVD may be worth noting [37].
Although plasma-free ADMA levels were found to be lower
in PKU children than healthy controls [40,45], inconsis-
tency about their antioxidant status [50,51] does not allow
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any resounding inference on the protective effects of
ADMA against PKU. Inconsistent results have been found
for plasma homocysteine levels [20,37,38,40,41], an
emerging cardiometabolic risk factor [39].
Finally, the study of the relationship between PKU diet
and cardiovascular risk would be of great interest if this
aspect could vary depending on dietary compliance and
tolerance to Phe. It was not possible to discuss this issue
because of the lack of data in most of the assessed studies.
Conclusions
Dietary treatment remains essential for PKU, despite the
appearance of new advances and strategies [8]. Long-
term dietary guidance and monitoring of the nutritional
status of subjects with PKU should be part of a life-long
follow-up programme. Doctors and dieticians should
prescribe and carefully monitor macronutrient and
micronutrient intake, growth and physical activity in PKU
subjects.
The existing literature about the possible relationship of
PKU diet with cardiovascular risk in children is scanty. This
narrative overview did not consider studies that included
only PKU children not compliant with diet. Although PKU
children compliant with diet may exhibit lower blood total
cholesterol and LDL-C levels than the healthy population,
they seem to display non-different cardiovascular risks.
Nevertheless, well-designed longitudinal studies, with
adequate statistical power, are still required to clarify the
potential underlying mechanisms related to PKU diet and
cardiovascular risk factors.
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1.4 Diet and gut micromiota: relationship and metabolic effect 
 
1.4.1 Definition of gut microbiota  
 
Over the last decade, the microbial composition of the gut (gut microbiota) has been widely 
investigated, and recognized as having an impact in various physiological and pathological 
conditions [1]. The gut microbiota includes more than 100 trillion cells of 400 species which is 
equivalent to ten times the total number of cells in the human body [2]. 
Currently, four major microbial phyla are known to represent over 90% of the bacterial 
component of gut microbiota: Firmicutes, Bacteroides, Proteobacteria and Actinobacteria. The 
majority of ʺgoodʺ bacteria harbouring the human gut microbiota are represented by Firmicutes 
and Cytophaga-Flavobacterium-Bacteroides (CFB). Firmicutes are sub-grouped in Clostridium 
coccoides (Clostridium cluster XIVa) and Clostridium leptum (Clostridium cluster IV); whereas 
CFB group is represented mainly by Bacteroides phyla with a great number of Prevotella and 
Porphyromonas [3]. Moreover, the human gut microbiota includes viruses, especially phages, 
Eukarya, as Fungi, Blastocystis, Amoebozoa, and Archaea [3]. 
Gut microbiota has been classified into three main enterotypes, each one owning specific 
metabolic features. Each enterotype is characterized by the relative abundance of one of the 
following genera: Bacteroides (more represented in enterotype 1), Prevotella (more abundant in 
enterotype 2), Ruminococcus (prevalent in enterotype 3). Prevalence of a specific enterotype can 
depend on long-term dietary habits; indeed high-fat and protein diet enhances the growth of 
enterotypes 1 and 3, while a diet rich in carbohydrates supports the raise of enterotype 2. Recent 
findings suggest that gut microbiota composition is influenced also by short-term dietary 
changes [3]. Both genetic and environmental factors are involved in influencing the inter-
individual diversity of gut microbiota. Among environmental ones, the interest of the scientific 
community in dietary factors has progressively increased, and the role of diet on the composition 
of gut microbiota has been particularly emphasized over the last years [3].  
 
1.4.2 The role of phenylketonuria diet on gut microbiota composition  
 
Diet is known to have a strong influence on the composition of intestinal microbiota [4]. 
The nutritional composition of PKU diets might change gut microbial ecology and affect host 
physiology [5]. At the present time only a Brazilian study analyzed gut microbiota in PKU 
children (age [DS] 4.24 [1.74]) in comparison to healthy children (6.06 [1.78]) [5]. In this study, 
as previously observed in healthy humans [6,7] and in PKU mice [8], the Bacteroidetes and 
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Firmicutes were the most dominant phyla found within in PKU and healthy children stool 
samples. However, significative difference in gut microbiota between PKU and healthy children 
were observed. The most significant differences in gut microbiota between patients and controls 
were observed for members of the Clostridiaceae, Erysipelotrichaceae, and Lachnospiraceae 
family, Clostridiales class, Coprococcus, Dorea, Lachnospira, Odoribacter, Ruminococcus, and 
Veillonella genera, which were enriched in the control group. Furthermore, three bacterial 
members—belonging to genera Prevotella and Akkermansia and to the Peptostreptococcaceae 
family—were enriched in the PKU group.  According to metagenome prediction, the 
microbiome of PKU patients presented fewer genes involved in starch and sucrose metabolism 
and in glycolysis/gluconeogenesis. Differences in microbial starch and glucose metabolism 
might also affect production of short-chain fatty acids (SCFAs), which might suggest lower 
SCFA production by the gut microbiota of PKU patients [5].  
 
1.4.3 Short chain fatty acids: pathways 
 
SCFAs are saturated aliphatic organic acids that consist of one to six carbons of which acetate 
(C2), propionate (C3), and butyrate (C4) are the most abundant (≥95%). Acetate, propionate, and 
butyrate are present in an approximate molar ratio of 60:20:20 in the colon and stool [9]. 
Acetate, which is the most abundant SCFA, is produced by most enteric bacteria as a 
fermentation product, but it is also formed by acetogenic bacteria, such as B. hydrogenotrophica, 
from H2 and CO2 or from formate via the Wood–Ljungdahl pathway (Figure 1). Acetogenic 
bacteria can produce three molecules of acetate from one molecule of glucose, but non-
acetogenic anaerobes, which comprise most of the microbiota, must dispose of reducing 
equivalents by forming other products in addition to (or instead of) acetate, including succinate, 
propionate, butyrate, formate, d-lactate, l‑lactate and ethanol (Figure 1). The relative synthesis of 
the different fermentation products varies according to the composition of the microbiota and 
environmental conditions, including pH, hydrogen partial pressure and available substrates [9].  
Propionate is mostly formed via the succinate pathway by Bacteroidetes and by some Firmicutes 
that belong to the Negativicutes class (such as Phascolarctobacterium succinatutens, Dialister 
spp. and Veillonella spp.). Succinate is a metabolic end-product for some bacteria under some 
environmental conditions, but specialist succinate utilizers, such as P. succinatutens, convert 
most of the succinate that is produced into propionate. Two other pathways also contribute to the 
formation of propionate: the acrylate pathway and the propanediol pathway (Figure 1). The 
acrylate pathway, in which lactate is a substrate, shows a limited distribution, whereas the 
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propanediol pathway, in which deoxyhexose sugars (such as fucose and rhamnose) are 
substrates, is present in some Firmicutes (including Roseburia inulinivorans and Ruminococcus 
obeum) and in Proteobacteria. The proportion of propionate that is present in total faecal SCFA 
correlates with the relative abundance of Bacteroidetes, which confirms that the succinate 
pathway is the dominant source of propionate [9]. 
Butyrate is produced by some Firmicutes using either the butyryl-CoA:acetate CoA-transferase 
enzyme or, less commonly, phosphotransbutyrylase and butyrate kinase to catalyse the final steps 
of the pathway (Figure 1). Species that use the butyryl-CoA:acetate CoA-transferase route 
include several of the most abundant species in the healthy gut microbiota (including 
Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Eubacterium hallii and 
Anaerostipes spp.) which are generally net users of acetate, such that the concentration of acetate 
in the gut lumen is determined by the balance of production, use and mucosal uptake. A subset of 
Lachnospiraceae, including E. hallii and Anaerostipes spp., can use lactate and acetate to 
produce butyrate. Thus, these organisms may have an important role in stabilizing the microbial 
ecosystem by preventing the accumulation of lactate. Only a few anaerobes are known to 
produce both propionate and butyrate, and they do so from different substrates: R. inulinivorans 
produces butyrate from glucose and produces propionate from fucose, whereas Coprococcus 
catus produces butyrate from fructose and produces propionate from lactate (via the acrylate 
pathway). 
Acetate, propionate and butyrate are rapidly adsorbed from the gut lumen, but their subsequent 
distribution, fate and effects on host cell metabolism differ. Butyrate is preferentially used 
as an energy source by gut epithelial cells, and its concentration in the systemic circulation is 
low. Propionate is mostly metabolized in the liver, and only acetate achieves relatively high 
concentrations (0.10–0.15 mM) in peripheral blood [10,11]. 
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Figure 1.  Pathways that are responsible for the biosynthesis of the major microbial metabolites 
that result from carbohydrate fermentation and bacterial cross-feeding. 
 
 
1.4.4 Short chain fatty acids: functions 
 
Short chain fatty acids have a wide range of actions. They are absorbed and metabolized rapidly 
by colonocytes, providing 60–70% of their energy requirements [12]. They also regulate fluid 
and electrolyte uptake via activation of apical NaC/HC exchange [12]. Their presence in the 
colon lowers the pH, thus preventing the overgrowth of pH-sensitive pathogenic bacteria. Human 
rectal SCFA infusions have also shown to increases planchnic blood flow and decrease gastrict 
one [13] 
Butyrate, in particular, plays an important role in intestinal health. It has been shown to have 
atrophic effect on colorectal and ileal mucosal cells but despite this, is able to maintain normal 
colonic phenotype via growth arrest, differentiation, and apoptosis, thereby lowering the risk of 
malignancy. Importantly, butyrate enhances the gastrointestinal innate immunity by acting as a 
relay for transducing information from the luminal environment to the mucosal immune system 
via up-regulation of toll like receptors expression [14]. These toll like receptors enable the 
epithelium to differentiate commensal flora from pathogens, via recognition of bacterial 
molecular patterns called PAMPs and induce the transcription of a panel of genes mediating 
immune and inflammatory responses [14].  
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In the last few decades, it has been hypothesized that SCFAs might play a key role in the 
prevention and treatment of metabolic syndrome, bowel disorders, and cancer [15,16]. Butyrate 
and propionate were shown to protect against diet-induced obesity and regulated the gut 
hormones [17]. Clinical studies showed that the administration of SCFAs has a positive effect on 
the treatment of ulcerative colitis, Crohn's disease, and antibiotic-associated diarrhea and obesity 
[18,19]. In obese subjects, propionate significantly increased the release of postprandial plasma 
peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) from colonic cells, and reduced the 
energy intake. Inulin-propionate ester administrated at 10 g per day over a period of 24 weeks 
significantly reduced weight gain, intra-abdominal adipose tissue distribution and 
intrahepatocellular lipid content, and improved insulin resistance in the inulin control group [19]. 
On the other hand, SCFAs also utilize as host energy source, therefore SCFAs are regarded as 
cause of increasing energy harvest from diet, linked to the obese phenotype by changes of gut 
microbiota composition [2]. 
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1.5 Aims of the study 
 
The general aim of this PhD thesis was to investigate the impact of phenylketonuric diet, 
principally carbohydrates quality, on metabolic profile, cardiovascular risk factors and fecal 
short chain fatty acids (SCFA) production in children with phenylketonuria. 
 
The primary aim was to evaluate nutritional intakes, especially dietary daily glycemic index and 
gycemic load, in PKU children compared with healthy children matched for age, sex and BMI z 
score and to evaluate whether an association may exist between the carbohydrate quality of the 
diet and the metabolic profile in PKU children. The results of this aim are presented in chapter 
2. 
 
The secondary aim, covered in chapter 3, was to determine cardiovascular risk factors in PKU 
children, on low-Phe diet, in MHP and in healthy children, on unrestricted diet, matched for age, 
sex and BMI z score and to evaluate whether an association may exist between the carbohydrate 
quality of the diet and the risk factors in PKU children.   
 
The third aim, described in chapter 4, was to compare gut microbiota biodiversity and its 
production of short chain fatty acids in PKU children and MHP children matched for age, sex 
and BMI z score.  
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Abstract Background and aims: No data exist in the current literature on the glycemic index (GI)
and glycemic load (GL) of the diet of phenylketonuric (PKU) children. The aims of this study were
to examine the dietary GI and GL in PKU children on a low-phenylalanine (Phe)-diet and to eval-
uate whether an association may exist between the carbohydrate quality and the metabolic pro-
ﬁle.
Methods: Twenty-one PKU children (age 5e11 years) and 21 healthy children, gender and age
matched, were enrolled. Dietary (including GI and GL) and blood biochemical assessments were
performed.
Results: No difference was observed for daily energy intake between PKU and healthy children.
Compared to healthy controls, PKU children consumed less protein (p Z 0.001) and fat
(p Z 0.028), and more carbohydrate (% of total energy, p Z 0.004) and ﬁber (p Z 0.009). PKU
children had higher daily GI than healthy children (mean difference (95% conﬁdence interval),
13.7 (9.3e18.3)) and higher GL (31.7 (10.1e53.2)). PKU children exhibited lower blood total
and low density lipoprotein cholesterol (LDL) levels (p < 0.01) and higher triglyceride level
(p Z 0.014) than healthy children, while glucose and insulin concentrations did not differ. In
PKU children the dietary GL was associated with triglyceride glucose index (Spearman’s correla-
tion coefﬁcient Z 0.515, p Z 0.034).
Conclusion: In PKU children a relationship of the dietary treatment with GI and GL, blood triglyc-
erides and triglyceride glucose index may exist. Improvement towards an optimal diet for PKU
children could include additional attention to the management of dietary carbohydrate quality.
ª 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.
Introduction
Phenylketonuria (PKU; OMIM 261 600) is an autosomal
recessive disorder of phenylalanine (Phe) metabolism
mainly due to mutations of the phenylalanine hydroxylase
(PAH) gene, which is needed to convert the essential
amino acid phenylalanine to tyrosine [1]. The loss of PAH
activity results in accumulation of Phe to neurotoxic levels
[1]. Various combinations of mutations result in a full
Abbreviation list: BMI, body mass index; GI, glycemic index; GL,
glycemic load; HDL, high-density lipoprotein; HOMA-IR,
homeostatic model assessment of insulin resistance; ICQC,
International scientiﬁc consensus summit from the International
Carbohydrate Quality Consortium; LDL, low-density lipoprotein;
MHP, mild hyperphenylalaninemia; PAH, phenylalanine
hydroxylase; Phe, phenylalanine; PKU, phenylketonuria; QUICK,
quantitative insulin sensitivity check index; TyG, triglyceride
glucose index; WHO, World Health Organization.
* Corresponding author.
E-mail address: elvira.verduci@unimi.it (E. Verduci).
http://dx.doi.org/10.1016/j.numecd.2016.11.002
0939-4753/ª 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical
Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
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spectrum of metabolic phenotypes ranging from mild
hyperphenylalaninaemia (MHP, blood Phe 120e360 mmol/
L) e in which dietary restriction is not necessary, to mild,
moderate and classical phenylketonuria (blood Phe levels
>360 mmol/L) which require dietary management [1].
The main goal of treatment for PKU is to maintain the
blood Phe within safe limits to prevent mental retardation
and ensure normal growth and life with good health
through adulthood [2e4]. The dietary treatment usually
begins immediately after conﬁrmation of PKU diagnosis in
newborns and should be continued throughout their life-
time [3,4].
Patients with PKU have to avoid foods rich in protein
(meat, ﬁsh, eggs, conventional bread, dairy products, nuts,
and seeds) [3]. Accordingly, the PKU diet is mainly made
up of low-protein natural foods (vegetables, fruits) and
special low protein products, which are low-protein vari-
ants of some foods such as bread, pasta and biscuits with a
protein content <1 g/100 g [3]. In Italy, the quantities of
the permitted natural foods are calculated from a method
of Phe equivalence (dependent upon howmuch Phe a food
contains for a given weight) [5]. The required amount of
daily protein is obtained from Phe-free protein substitutes
providing essential amino acids in suitable proportions [3].
In PKU patients the issue of overweight and obesity has
been highlighted [6], although the prevalence of obesity
was observed similar to general populations both in PKU
children [7] and adults [8,9]. The metabolic proﬁle of PKU
patients has been studied in the past (e.g. Refs. [8e10]).
Only a study compared the metabolic syndrome between
PKU and healthy subjects and no difference in the preva-
lence was reported [8].
The high energy content of Phe-free protein substitutes
and the “avoidance” of sporting activities have been sug-
gested to be factors inﬂuencing the tendency to over-
weight/obesity in the PKU population [6]. The
uncontrolled consumption of special low protein products
could be another factor predisposing to obesity [6]. In se-
vere PKU phenotypes (with natural protein tolerance less
than 10 g/day), the special low protein products may
provide up to 50% of energy requirements [6]. Moreover,
Rocha et al. [6] highlighted that in some low protein
products it is common to add glucose, dextrose or sugar as
ingredients, and this may increase the sugar intake in PKU
[6].
The glycemic index (GI) was developed to systemati-
cally classify foods according to their ability to raise
postprandial glycemia [11]. Since the overall impact of one
food on postprandial response is due to the combination of
GI and the amount of carbohydrates in that food, a derived
index has been proposed, namely glycemic load (GL) [11].
Subsequently, GL was standardized to the energy of the
food portion consumed (GL/1000 kJ) for a better repre-
sentation of carbohydrate-based foods combined with fat
and protein [11].
In 2015 the International Scientiﬁc Consensus Summit
from the International Carbohydrate Quality Consortium
(ICQC) [12] recommended that low GI and low GL should
be considered in the context of a healthy diet [12]. The
ICQC stated that low GI/GL diets reduce the risk of type 2
diabetes and could reduce total body fat mass [12]. No data
exist in the current literature on GI and GL in PKU children.
The primary aim of the present study was to examine
the dietary glycemic index and glycemic load in PKU
children on low-Phe diet. Secondary aim was to evaluate
whether an association may exist between the carbohy-
drate quality and their metabolic proﬁle.
Methods
This observational case-control study examined 21 PKU
primary school children (age 5e11 years) gender and age
(6 months) matched with 21 healthy controls, consecu-
tively admitted to the Department of Pediatrics, San Paolo
Hospital, Milan, from January 2014 to September 2014.
Inclusion criteria were: gestational age 37e42 week in-
clusive, weight at birth 2500 g, single birth, no congen-
ital malformation, white parents. Exclusion criteria were:
having endocrine disorders, chronic liver diseases or
overweight/obesity. PKU children non-compliant with the
recommended diet were also excluded. Overweight/
obesity was deﬁned in accordance with the International
Obesity Task Force [13]. PKU children were deﬁned as
compliant to the diet when the annual mean Phe levels,
monitored monthly by the Guthrie test [14], was within
the range 120e360 mmol/L. Phenylketonuric children were
detected by a newborn screening test and periodically
monitored in our department since diagnosis.
A medical history was collected at recruitment from
parents by a standardized questionnaire during a personal
interview conducted by the same pediatrician that also
saw the children for a general examination, and evaluated
the Tanner stage of puberty [15]. Moreover, the pediatri-
cian took anthropometric measurements of children,
assisted by an experienced operator. Body weight and
height were measured using a mechanical column scale
(seca 711; seca GmbH & KG, Hamburg, Germany) with an
integrated measuring rod (seca 220; seca GmbH & KG). The
body mass index (BMI) was calculated from the ratio of
weight to height squared (kg/m2). BMI z-scores were
calculated and adjusted for age and gender by using Cole’s
LMS method [16] and Italian reference data [17]. The par-
ents of eligible children or their legal guardian received a
detailed explanation of the study, and signed a consent
form. The hospital Ethics Committee approved the study
protocol and gave ethical clearance.
Dietary assessment and daily GI and GL
For each child, the dietary intake, including beverages, was
recorded by means of a food diary ﬁlled out by parents for
three consecutive days (two weekdays and one weekend
day). Parents received instructions about the method for
weighing and recording food. They were trained by a
dietitian to weigh each food item offered to their child
before consumption, to weigh leftovers and to record the
weights each time [18]. Quantiﬁcation and analysis of the
energy intake and nutrient composition were performed
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with an ad hoc PC software (MètaDieta, Me.Te.Da S.r.l.,
San Benedetto del Tronto, Italy). Vegetable intake quanti-
ﬁcation excluded tuber and legumes in accordance with
the World Health Organization (WHO) [19].
For each food, the GI value was derived from the Italian
[11] or International [20e22] tables. If there was a
discrepancy between the tables [20e22] then the mean
value was used. For a food not included in the Italian or
International tables, the GI value was determined at the
Department of food science, University of Parma (Italy),
using the Food and Agriculture Organization/World Health
Organization’s method [23] and in accordance with the
International Standards Organization guideline [24]. Then,
to ﬁnd out the GI of these foods healthy volunteers were
recruited, after an informed consent was signed. On the
day before the test the volunteers consumed a standard-
ized dinner. Foods with known content of fermentable
dietary ﬁber were forbidden in order to avoid any second
meal effect. After fasting overnight, volunteers were tested
for assessed foods (with 500 mL of still mineral water)
once each, and the standardized food (50 g of glucose)
three times, in random order on separate days. Blood
samples were taken by ﬁnger-prick. Whole capillary blood
glucose was measured by an automatic analyzer (YSI
Stat2300, YSI Inc., Yellow Springs, OH). Blood samples
were collected at 15, 30, 45, 60, 90 and 120 min after
starting to eat.
Mean GI of each meal, was calculated by the following
formula [25]:
GImeal Z (SiZ1, ., n GIfood i * grams of carbohydratesfood i)/
total grams of carbohydratesmeal
Daily mean GI, was calculated as:
GIdailyZ (SiZ1, ., n GImeal i * grams of carbohydratesmeal i)/
daily total grams of carbohydrates
The glycemic load for each meal was calculated:
GLmeal Z SiZ1, ., n GLfood i
Biochemistry
Fasting blood samples of our study population were
analyzed at the hospital laboratory of biochemistry for
total cholesterol, high-density-lipoprotein (HDL) choles-
terol, low-density-lipoprotein (LDL) cholesterol, tri-
glycerides, insulin and glucose on the Cobas 6000
analyzer series, c501 and e601 modules (Roche Diagnostics
GmbH, Hoffmann-La Roche ltd, Mannheim, Germany).
The triglycerides/HDL ratio was calculated as a predic-
tor of smaller dense low-density-lipoprotein, a cardiovas-
cular risk factor [26]. The homeostatic model assessment
of insulin resistance (HOMA-IR) mainly reﬂecting insulin
resistance in the liver, was calculated as the product of
fasting glucose (mmol/L) and fasting insulin (mU/mL)
divided by 22.5 [27]. The quantitative insulin sensitivity
check (QUICK) index was calculated as 1/(log10 fasting
plasma insulin in mU/mL þ log10 glucose in mg/dL) to
evaluate insulin sensitivity [28]. Pancreatic b-cell function
was evaluated by HOMA-b as (20  fasting insulin in mU/
mL)/(fasting glucose in mmol/L3.5) [27]. The triglyceride
glucose index (TyG index), that seems to reﬂect mainly
peripheral insulin resistance, was calculated as Log [fasting
triglycerides (mg/dL)  fasting glucose (mg/dL)/2] [29,30].
Statistical analysis
Descriptive data are reported as mean and standard de-
viation (SD), and median and the 25the75th centile.
Normality of the distribution of continuous variables was
assessed by the KolmogoroveSmirnov test. For continuous
variables, comparison between groups was performed by
the Student’s t-test and the ManneWhitney or Wilcoxon
test, as appropriate. Triglycerides, insulin, and HOMA-IR
were not normally distributed, and log 10-transformation
was used for analysis. For clarity of interpretation, results
are expressed as untransformed values. The association of
dietary daily glycemic index, glycemic load and GL/1000 kJ
with glucose-metabolism and lipid variables was assessed
by Spearman’s correlation coefﬁcient. All values of p < 0.05
were considered to indicate statistical signiﬁcance (two-
tailed test). The statistical package for social sciences
(SPSS) version 20.0 (SPSS Inc., Chicago, IL, USA) for Win-
dows (Microsoft, Redmond, WA, USA) was used for the
statistical analysis.
Results
The sample examined comprised 9 boys and 12 girls for
each group. Mean (SD) age of children was 8.0 (2.2) years.
No signiﬁcant difference between PKU and healthy chil-
dren was found for BMI z-score (0.08 (0.74) vs. 0.03
(0.65), p Z 0.801). In PKU children, mean (SD) blood Phe
levels at the recruitment was 243.7 (72.3) mmol/L.
Dietary intake of energy, macronutrients, ﬁber, fruit and
vegetables are reported in Table 1. PKU children consumed
lower proteins and fats, and higher carbohydrates (% of
total energy) and ﬁbers than healthy children. The rec-
ommended carbohydrate intake was exceeded by 71.4% of
PKU children and 19.0% of controls (p Z 0.002). All PKU
children had a lower protein intake than the recom-
mended upper limit compared to 57.1% of healthy children
(p Z 0.001). No signiﬁcant difference between the two
groups was observed for the proportion of children who
were within the recommended range for energy and fat
(minimum p Z 0.454). Ten (47.6%) PKU children and 5
(23.8%) controls were in line with the recommendation for
ﬁber intake (8.4 g/1000 kcal), p Z 0.197. PKU children
had a greater ﬁber intake from vegetables than controls
(p Z 0.002) and consumed more vegetables (p Z 0.013).
Table 2 shows the overall daily GI and GL of diet and of
each meal in PKU and healthy children. Overall dietary GI,
as well as at breakfast, lunch and dinner, was higher in
PKU than healthy children (0.001 < p < 0.026). Overall
dietary GL, as well as at lunch and dinner, was higher in
PKU than healthy children (0.004 < p < 0.011). The mean
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(SD) daily GL/1000 kJ was higher in PKU than in healthy
children (23.9 (8.4) vs. 18.2 (5.0) kJ1, p Z 0.001).
Table 3 reports daily dietary intake of energy, macro-
nutrients and ﬁber consumed by Phe-free protein sub-
stitutes and special low protein products in PKU children.
These products accounted for more than 60% of overall
daily energy, protein and carbohydrate intake, and for
about a third of fat and ﬁber intake. Except for protein,
intake of energy, macronutrients and ﬁber was higher for
special low protein products than for Phe-free protein
substitutes (maximum p < 0.01).
Table 4 shows the glucose metabolism and blood lipid
proﬁle variables in PKU and healthy children. Glucose
metabolism variables did not differ between PKU and
healthy children (minimum p Z 0.052), except for triglyc-
eride glucose index that was higher in PKU children
(p Z 0.020). Compared to healthy controls, PKU children
exhibited lower blood total (p< 0.001) and LDL (pZ 0.006)
cholesterol, higher triglyceride levels (pZ 0.014) and higher
triglycerides/HDL ratio (pZ 0.015). In PKU children the di-
etary GL was associated with triglyceride glucose index
(Spearman’s correlation coefﬁcient Z 0.515, p Z 0.034).
Association of dietary GL with blood triglycerides was close
to statistical signiﬁcance (Spearman’s correlation
coefﬁcient Z 0.446; p Z 0.064). Neither GI nor GL were
associated with any other metabolic variables (minimum
pZ 0.104).
Discussion
This is the ﬁrst study evaluating the dietary glycemic index
and glycemic load in PKU children on a strict diet.
The results showed that while daily energy intake was
similar between PKU and healthy children, as previously
reported [31,32], PKU children had lower fat and protein
intake, and higher carbohydrate and ﬁber intake, as also
observed in English/French [33] and Greek (except pro-
tein) [31] PKU children. Anyhow, it should be pointed out
that in PKU subjects protein intake should be higher than
the recommended value for healthy subjects [34,35], due
to the decreased protein utilization for amino acids that
Table 1 Daily dietary intake of energy, macronutrients, ﬁber, fruit and vegetables in phenylketonuric (PKU) and healthy children.
Variable PKU children (n Z 21) Healthy children (n Z 21) P-valuea Reference valuesb
Mean (SD) Median (25the75th
centile)
Mean (SD) Median (25the75th
centile)
Energy
kcals 1480.5 (298.4) 1443.0 (1276.6e1795.3) 1540.3 (245.8) 1517.5 (1313.3e1746.6) 0.570 Boys: 1400
e2610 kcal (AR)
Girls: 1290
e2360 kcal (AR)
kcals/kg weight 59.2 (13.4) 59.3 (46.6e69.2) 58.3 (14.1) 59.9 (48.9e67.4) 0.760
kJ 6194.5 (1248.5) 6037.5 (5341.2e7511.4) 6444.7 (1028.2) 6349.3 (5494.7e7307.8) 0.570
Protein
g 36.6 (11.4) 34.8 (28.4e43.5) 57.6 (10.3) 55.0 (49.5e63.4) 0.001d 16e39 g (AR)
% energy 9.8 (1.9) 9.6 (8.3e11.2) 15.0 (1.7) 14.8 (14.1e16.2) 0.001d 12e15% (RI)
g/kg weight 1.4 (0.3) 1.5 (1.3e1.6) 2.1 (0.4) 2.1 (1.9e2.3) 0.002d boys: 0.76e0.79 g/
kg (AR)
girls: 0.76e0.77 g/kg
(AR)
Carbohydrate
g 235.4 (58.7) 230.3 (193.5e276.5) 213.2 (31.9) 213.0 (188.5e235.0) 0.065
% energy 63.4 (6.8) 63.1 (58.8e66.8) 55.6 (4.9) 55.7 (53.0e59.5) 0.004d 45e60% (RI)
Fat
g 45.3 (12.7) 43.9 (37.7e55.1) 54.1 (12.7) 52.7 (44.3e63.9) 0.025d
% energy 27.9 (7.0) 28.8 (23.4e31.4) 31.5 (4.5) 30.7 (28.4e35.7) 0.028d 20e35% (RI)
Fiber
Overall (g) 13.2 (4.1) 13.0 (10.8e15.6) 10.5 (2.8) 10.5 (8.4e12.0) 0.009d
Overall (g)/1000 kcal 9.2 (3.6) 8.4 (7.4e9.3) 6.9 (2.2) 6.6 (7.4e9.3) 0.012d 8.40 g/1000 kcal (AI)
From fruit (g) 2.0 (1.8) 1.4 (0.6e3.7) 1.6 (1.4) 1.6 (0.3e2.8) 0.377
From vegetables (g) 3.2 (1.4) 3.2 (1.9e4.0) 1.5 (1.0) 1.2 (0.7e2.3) 0.002d
From other foods (g)c 8.0 (4.3) 7.4 (4.5e9.5) 7.3 (2.0) 7.0 (5.8e8.8) 0.338
Fruit and vegetables
Overall (g) 281.7 (120.5) 253.3 (179.9e360.8) 219.6 (110.6) 214.1 (155.0e273.0) 0.086 400 g
Fruit (g) 98.4 (84.6) 80.0 (34.0e174.5) 108.6 (74.2) 111.7 (58.3e143.3) 0.713
Vegetables (g) 183.3 (87.0) 173.3 (120.0e213.7) 111.0 (70.6) 102.4 (63.4e144.2) 0.013d
AR, average requirement; RI, reference intake; AI, adequate intake.
a Student’s t-test or ManneWhitney test.
b Energy, macronutrients and ﬁber [34]; amount of fruit and vegetables [19].
c Excluded fruit and vegetables.
d Statistically signiﬁcant.
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are the primary source of protein in PKU disease [4].
Indeed, in this study, all PKU children had a protein intake
lower than 12.3% of energy. The 71.4% and 14.3% of PKU
children had higher carbohydrate and fat intakes, respec-
tively, than the recommended upper limit for healthy
children and 52.4% of children had an inadequate ﬁber
intake [34]. Within the healthy group 19.0%, 42.9% and
28.6% of children exceeded the recommended intake for
carbohydrate, protein and fat, respectively, while 76.2%
had inadequate intake of ﬁber [34]. Unlike healthy chil-
dren, PKU children showed an adequate mean ﬁber intake.
No data have yet been published on GI and GL in the
PKU diet. This study showed that overall dietary GI and GL
were higher in PKU than in healthy children. Only 9.5% of
healthy children and none of the PKU children had GI  45,
which could be associated with reduced risk of chronic
disease in adult cohort studies [36]. This cut-off value
remains to be further investigated in children. Addition-
ally, PKU children showed higher GI and GL values at lunch
and dinner and a higher GI value at breakfast than did
healthy children. This could be due to consumption of
special low protein products mainly in these speciﬁc
meals. The special low protein products accounted for
about 50% of total energy intake and more than 60% of
carbohydrate intake, suggesting the importance of man-
agement of these products for possibly improving the di-
etary intake. Some special low protein products are
commonly added with glucose, dextrose or sugar as in-
gredients, which may increase their glycemic index [6]. A
higher carbohydrate composition than conventional foods
was also found in 92% of special low protein products in a
recent Portuguese study [37].
PKU children did not show alteration in blood glucose
and insulin metabolism, despite the higher overall diet GI
Table 2 Glycemic index and glycemic load of overall daily diet and meals in phenylketonuric (PKU) and healthy children.
Variable PKU children (n Z 21) Healthy children (n Z 21) P-valuea
Mean (SD) Median (25the75th centile) Mean (SD) Median (25the75th centile)
Glycemic index
Overall diet 62.2 (5.8) 61.6 (58.9e66.9) 48.5 (8.4) 50.6 (45.0e53.9) <0.001c
Breakfast 51.6 (9.5) 52.8 (46.2e58.2) 40.8 (15.6) 42.7 (26.8e50.1) 0.026c
Morning snackb 48.8 (18.2) 42.6 (34.4e64.6) 49.7 (12.0) 46.7 (39.1e61.5) 0.792
Lunch 70.9 (5.5) 70.9 (66.4e76.1) 52.5 (4.5) 53.5 (48.4e56.2) <0.001c
Afternoon snack 51.5 (11.5) 50.5 (44.8e57.9) 48.1 (11.8) 50.9 (42.3e57.4) 0.319
Dinner 68.2 (6.8) 70.0 (65.3e72.8) 50.5 (6.6) 52.6 (46.6e54.2) 0.005c
Glycemic load
Overall diet 148.2 (35.2) 151.5 (123.4e173.2) 116.5 (33.9) 110.6 (95.0e132.3) 0.007c
Breakfast 17.8 (9.6) 15.9 (11.2e25.7) 14.6 (11.2) 12.2 (6.4e20.9) 0.327
Morning snackb 6.2 (8.3) 3.9 (1.0e7.1) 9.0 (4.9) 9.3 (5.3e13.0) 0.957
Lunch 53.3 (14.6) 51.6 (44.9e62.9) 38.5 (12.1) 36.0 (30.2e45.3) 0.004c
Afternoon snack 19.4 (12.6) 16.3 (10.2e27.3) 14.4 (8.6) 12.1 (7.7e23.7) 0.173
Dinner 55.2 (20.3) 53.2 (43.0e60.8) 38.3 (13.9) 40.7 (29.8e49.8) 0.011c
a Student’s t-test or ManneWhitney test.
b Nine PKU children and 9 healthy children did not report any morning snack during the food diary recording.
c Statistically signiﬁcant.
Table 3 Daily dietary intake of energy, macronutrients and ﬁber, consumed by phenylalanine (Phe)-free protein substitutes and special low
protein products in phenylketonuric children (n Z 21).
Variable Phe-free protein substitutes
and special low protein products
Phe-free protein substitutes Special low protein products P-valuea
Mean (SD) Median (25the75th
centile)
Mean (SD) Median (25the75th
centile)
Mean (SD) Median (25the75th
centile)
Dietary intake
Energy (kcal) 891.3 (239.9) 873.5 (764.0e1062.6) 204.4 (73.9) 211.0 (155.2e249.2) 686.9 (238.7) 684.5 (577.6e830.5) <0.001b
Protein (g) 25.9 (8.9) 22.9 (19.6e31.4) 24.4 (8.6) 21.1 (18.0e30.8) 1.5 (0.7) 1.5 (0.8e2.0) <0.001b
Carbohydrate (g) 161.5 (49.6) 154.5 (126.5e196.7) 17.8 (10.7) 17.3 (11.0e25.2) 143.6 (51.3) 138.5 (110.7e176.6) <0.001b
Fat (g) 14.8 (6.2) 16.1 (10.4e18.7) 4.1 (4.3) 3.8 (0.1e7.1) 10.8 (5.8) 9.5 (5.9e16.5) 0.003b
Fiber (g) 4.8 (4.3) 3.7 (1.8e6.6) 0.04 (0.10) 0 (0.0e0.0) 4.7 (4.3) 3.7 (1.8e6.6) <0.001b
Dietary intake/overall dietary intake
Energy (%) 61.2 (14.4) 64.5 (57.6e70.7) 14.2 (6.3) 13.7 (10.6e16.3) 46.5 (14.3) 47.4 (43.9e56.2) <0.001b
Protein (%) 70.1 (10.1) 72.1 (64.3e76.8) 65.9 (9.9) 68.0 (60.1e73.4) 4.1 (2.1) 4.0 (2.5e6.1) <0.001b
Carbohydrate (%) 69.7 (16.8) 76.7 (61.3e79.6) 8.3 (6.2) 6.6 (4.1e12.0) 61.5 (17.7) 66.9 (56.3e71.3) <0.001b
Fat (%) 32.9 (10.8) 34.9 (26.9e39.8) 9.2 (10.3) 6.3 (0.2e16.2) 23.8 (10.1) 22.6 (19.0e28.9) 0.004b
Fiber (%) 33.7 (21.3) 27.2 (17.8e51.6) 0.2 (0.5) 0 (0.0e0.0) 33.5 (21.1) 27.1 (17.8e51.6) <0.001b
a Student’s t-test or ManneWhitney test (Phe-free protein substitutes versus special low protein products).
b Statistically signiﬁcant.
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and GL than healthy controls. A Brazilian study evaluated
insulin and HOMA in normal weight PKU children (mean
age 9 years) observing a median of 26.4 pmol/L and 0.7,
respectively [38], that are similar to values found in this
study.
A positive associationwas observed between the overall
diet GL and the triglyceride glucose index, suggesting a
possible relationshipbetweencarbohydratequalitydiet and
peripheral insulin resistance. It should be pointed out that
the lack of association between GL and other insulin sensi-
bility and resistance indices, might be at least in part due to
the low protein intake in the PKU diet. A higher protein
intake, mainly from animal foods, could stimulate secretion
of an insulin-like growth factor I (IGF-I) and insulin [39,40].
Moreover it should be noted that in this study insulin
resistance and insulin sensitivity have been evaluated by
surrogate indices rather than by a hyperinsulinemic-
euglycemic clamp (the gold-standard method).
Regarding blood lipid proﬁle, PKU children exhibited
lower total and LDL cholesterol and higher triglyceride
levels than did healthy controls, in accordance with previ-
ous studies [10,31]. These results may be attributed, at least
in part, to the PKU diet, which is characterized by the
avoidance of animal foods [3,38], and to a higher than the
recommended upper limit of carbohydrate intake [34] in
PKU children. Lastly, it should be noted that a relationship
might exist between dietary GL and triglycerides, as previ-
ously found both in healthy children [41] and in adults [42].
Within the limitations of this study, it is possible to
conclude that in PKU children the dietary treatment could
be associated with higher dietary GI, GL and blood triglyc-
eride level and lower total and LDL cholesterol levels.
Moreover a relationship between the quality of carbohy-
drates consumed and the triglyceride glucose index may
exist. An improvement towards an optimal diet for PKU
children could include additional attention to the manage-
ment of dietary carbohydrate quality, with particular focus
on special low protein products. Longitudinal, adequately-
powered studies are needed to clarify the mutual in-
terrelationships between the diet and metabolic proﬁle of
PKU children.
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Chapter 3:  
METABOLIC PROFILE AND RISK OF 
CARDIOVASCULAR DISEASE IN CHILDREN WITH 
HYPERPHENYLALANINEMIA
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3.1 Introduction 
 
Reduction of animal origin lipids and cholesterol intakes, which is one of the main 
characteristics of the PKU diet, could be considered a non-atherogenic diet [1]. 
Arteriosclerosis is related to the presence and intensity of the known cardiovascular risk factors 
like family history, age, gender, nutrition/diet, physical inactivity, lipid levels, 
overweight/obesity, diabetes mellitus, inflammatory markers [2]. It has a long, asymptomatic, 
preclinical period. Pathological changes in the arteries of children develop decades before 
clinical manifestation of the disease. Some authors suggest that specific types of lesions 
occurring in younger ages (fatty streaks) are transformed into another type of lesions (fibrous 
plaques) in young adults and middle-aged persons, while others demonstrate that the progression 
from fatty streaks to plaque might be arrested in childhood and does not begin to a significant 
extent until after puberty in males and after menopause in females [3]. 
Carotid artery intima–media thickness (cIMT) is considered a significant predictive marker of 
generalized atherosclerosis because of its correlation with coronary artery disease and it may 
predict future cardiovascular events in adults [4]. It is also recommended by the American Heart 
Association as a noninvasive imaging parameter for detecting atherosclerosis [5,6]. In 2007, 
Lorenz et al. published a systematic review and meta-analysis of eight relevant general 
population-based studies that had reported on the ability of cIMT to predict future CV end 
points, involving a total of 37,197 subjects followed for a mean of 5.5 years [7]. They reported 
that for an absolute cIMT difference of 0.1 mm, the future risk of myocardial infarction increases 
by 10–15%, and the stroke risk increases by 13–18%. 
The primary aim of this study was to determine early atherosclerotic changes (evaluated by 
cIMT), and several cardiovascular-related risk factors (for example blood pressure (BP), plasma 
total homocysteine (tHcy) levels, Apolipoprotein B/Apolipoprotein A1, lipoprotein (a)) in 
children with PKU, on phe-restricted diet and in MHP and in healthy children, on unrestricted 
diet. The secondary aim was to evaluate whether an association may exist between cIMT and 
their dietary glycemic index and glycemic load. 
 
 
3.2 Materials and methods 
 
This observational case-control study examined 31 PKU children (age 4–13 years) gender and 
age (± 6 months) matched with 31 MHP children and 31 healthy controls, consecutively 
admitted to the Department of Pediatrics, San Paolo Hospital, Milan, from March 2014 to 
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September 2015. Inclusion criteria were: gestational age 37–42 week inclusive, weight at birth ≥ 
2500 g, single birth, no congenital malformation, white parents. Children with endocrine 
disorders and chronic liver diseases were excluded. PKU children non-compliant with the 
recommended diet were also excluded. PKU children were defined as compliant to the diet when 
the annual mean Phe levels, monitored monthly by the Guthrie test [8], was within the range 
120–360 µmol/L. Phenylketonuric children were detected by a newborn screening test and 
periodically monitored in our department since diagnosis.  
A medical history was collected at recruitment from parents by a standardized questionnaire 
during a personal interview conducted by the same pediatrician that also saw the children for a 
general examination, and evaluated the Tanner stage of puberty [9]. Moreover, the pediatrician 
took anthropometric measurements of children, assisted by an experienced operator. Body 
weight and height were measured using a mechanical column scale (seca 711; seca GmbH & KG, 
Hamburg, Germany) with an integrated measuring rod (seca 220; seca GmbH & KG). The body 
mass index (BMI) was calculated from the ratio of weight to height squared (kg/m2). BMI z-
scores were calculated using WHO Anthro Software [10]. Waist circumference (WC) was 
measured using the measuring tape seca 203 (seca GmbH & KG) to the nearest 0.1 cm at the 
mid-point between the iliac crest and the lower edge of the ribs at the end of a normal expiration. 
WC was defined high when was above 95th percentile [11]. Blood pressure (BP) was measured 
by an oscillometric technique with Dinamap Procare blood pressure monitor (GE Medical 
Systems, Freiburg, Germany). Measurement and definition of high blood pressure were in 
accordance with the US National High Blood Pressure Education Program [12]. High blood 
pressure was defined as systolic BP and/or diastolic BP above the 95th percentile according to 
gender, age, and height; while prehypertension was defined as systolic BP and/or diastolic BP 
from the 90th to 95th percentile on repeated measurements Physical activity of children included 
in the present study was assessed by validated questionnaires [13,14]. 
The parents of eligible children or their legal guardian received a detailed explanation of the 
study, and signed a consent form. The hospital Ethics Committee approved the study protocol 
and gave ethical clearance. 
 Dietary assessment and daily GI and GL 
For each child, the dietary intake, including beverages, was recorded by means of a food diary 
(showed in figure 1) filled out by parents for three consecutive days (two weekdays and one 
weekend day). Parents received instructions about the method for weighing and recording food. 
They were trained by a dietitian to weigh each food item offered to their child before 
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consumption, to weigh leftovers and to record the weights each time [15]. Quantification and 
analysis of the energy intake and nutrient composition were performed with an ad hoc PC 
software (MètaDieta, Me.Te.Da S.r.l., San Benedetto del Tronto, Italy). Vegetable intake 
quantification excluded tuber and legumes in accordance with the World Health Organization 
(WHO) [16]. Dietary glycemic index and dietary glycemic load were performed using a 
previously described method [17] (Chapter 2). 
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Biochemistry 
Fasting blood samples of study population were analyzed at the hospital laboratory of 
biochemistry for total cholesterol, high-density-lipoprotein (HDL) cholesterol, low-density-
lipoprotein (LDL) cholesterol, triglycerides (Tg), insulin, apolipoprotein A1 (ApoA1) and 
apolipoprotein B (ApoB), lipoprotein (a), glucose, vitamin B12 (B12), homocysteine (Hcy), 
folate and high sensitivity C-Reactive Protein (hsCRP) on the Cobas® 6000 analyzer series, 
c501 and e601 modules (Roche Diagnostics GmbH, Hoffmann-La Roche ltd, Mannheim, 
Germany). 
The Apolipoprotein B/Apolipoprotein A1 ratio was calculated to represent the balance between 
proatherogenic and atherogenic lipoproteins, it was considered a better predictor of 
cardiovascular risk in adults than any of the cholesterol indexes [18,19]. 
The LDL cholesterol/Apolipoprotein B and triglycerides/HDL cholesterol ratios were calculated 
as a predictor of the low-density-lipoprotein size and have been used as marker of atherogenicity 
of LDL cholesterol [1,20-22]. Moreover, Tg/HDL cholesterol was calculated to identify 
individuals with atherogenic dyslipidemia, cardiometabolic risk [23] and ratio ≥ 2.2 has been 
recently suggested as predictor of impaired glucose tolerance in overweight/obese youth [24]. 
The homeostatic model assessment of insulin resistance (HOMA-IR), mainly reflecting insulin 
resistance in liver, was calculated as the product of fasting glucose (mmol/L) multiplied for 
fasting insulin (µU/mL) divided by 22.5 [25]. Insulin resistance was defined as HOMA-IR >3.16 
according to the most recent cut-off for the pediatric population [26]. The quantitative insulin 
sensitivity check (QUICK) index was calculated as 1/(log10 fasting plasma insulin in µU/mL + 
log10 glucose in mg/dL) to evaluate insulin sensitivity [27]. Pancreatic β-cell function was 
evaluated by HOMA-β as (20 × fasting insulin in µU/mL)/(fasting glucose in mmol/L−3.5) [25]. 
The triglyceride glucose index (TyG index), that seems to reflect mainly peripheral insulin 
resistance, was calculated as Log [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2] 
[28,29]. 
Degree of background inflammation was measured by level of hsCRP. Values 1 to < 3 mg/l were 
considered to be mildly elevated, and those ≥3 mg/l were considered to be elevated [30]. 
Regarding tHcy, only reference values for adults were found in the literature [31]. Elevated 
plasma homocysteine levels (>12 µmol/l; moderate hyperhomocysteinemia) were considered 
cytotoxic [31]. 
The atherogenic index of plasma (AIP), a strong predictor of atherosclerosis [33] was calculated 
as: Log [fasting triglycerides (mg/dL)/ fasting HDL (mg/dL)]. AIP value of under 0.11 is 
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associated with low risk of CVD; the values between 0.11 to 0.21 and upper than 0.21 are 
associated with intermediate and increased risks, respectively [33]. 
Ultrasound examination 
All ultrasound examinations of the study were performed with the ultrasound device: GE Logiq 
9, GE Healthcare Medical System, Milwaukee, Wisc., USA, 10–12 MHz. The combined 
thickness of the intimal and medial arterial wall components of the common carotid artery was 
determined with a linear transducer by an experienced pediatrician. Subjects were examined in a 
supine position with a slightly overextended neck in a two-dimensional presentation of the 
longitudinal view of the vessel. cIMT of the far wall was measured 1–2 cm below the bifurcation 
of the common carotid artery at the late diastolic phase.  
 
Measurement of fecal calprotectin 
 
FC concentration was measured in samples using the CALPROLAB Calprotectin ELISA 
(Calpro, Lysaker, Norway) kit. The lower detection limit of the assay is 15.6 mg/kg.  
  
Statistical Analysis 
Descriptive data are reported as mean and standard deviation (SD), and median and the 25th–75th 
centile. Normality of the distribution of continuous variables was assessed by the Kolmogorov-
Smirnov test. Comparison among groups was performed by Kruskal–Wallis test or ANOVA, as 
appropriated.  
The association of dietary daily glycemic index, glycemic load and cardiovascular risk factors 
was assessed by Pearson’s or Spearman’s correlation coefficient as appropriate. Finally, we 
adjusted the obtained p-values using the Bonferroni correction. The statistical package for social 
sciences (SPSS) version 20.0 (SPSS Inc., Chicago, IL, USA) for Windows (Microsoft, Redmond, 
WA, USA) was used for the statistical analysis. 
 
3.3 Results  
 
The examined sample was comprised of 14 males and 17 girls for each group. Mean (SD) age of 
children was 7.5 (2.9) years. No significant differences among PKU, MHP and healthy children 
were found for anthropometric measurements and systolic and diastolic blood pressure (Table 1). 
In PKU children, annual mean (SD) blood Phe levels was 294.8 (128.3) µmol/L.  
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Table 1. Anthropometric measurements and systolic and diastolic blood pressure in PKU, MHP 
and healthy children. 
 PKU children 
 (n=31) 
MHP children  
(n=31) 
Healthy children 
 (n=31) P-value 
Variable Mean (SD) Mean (SD) Mean (SD)  
Weight, kg 27.73 (12.06) 29.60 (13.08) 31.18 (12.99) 0.572 
Height, m 1.23 (0.16) 1.27 (0.20) 1.29 (0.21) 0.840 
BMI, z-score 0.67 (0.98) 0.67 (1.21) 0.53 (0.82) 0.938 
Waist circumference, cm 57.65 (7.26) 58.41 (8.98) 60.30 (9.39) 0.687 
Systolic blood pressure, mm Hg 101.97 (10.00) 101.04 (11.39) 99.90 (9.85) 0.737 
Diastolic blood pressure, mm Hg 57.71 (6.47) 57.04 (6.30) 57.55 (8.92) 0.970 
 
Dietary intake of energy, macronutrients, fiber, fruit and vegetables are reported in Table 2. PKU 
children consumed lower proteins and higher carbohydrates (% of total energy) and fibers than 
MHP and healthy children. Moreover, PKU consumed a higher fruit and vegetables (overall and 
only vegetables) intake than MHP and healthy children. The recommended carbohydrate intake 
[34] was exceeded by 74.2% of PKU children and by 19.4% of MHP and controls. Moreover, it 
should be noted that 16% of healthy children consumed carbohydrate intake less than 
recommended. Only 1 (3.1%) PKU, 11 (35.5%) MHP and 13 (41.9%) healthy children exceeded 
the recommended upper level for protein intake. Six (19.4%) PKU and MHP and 7 (22.6%) 
healthy children exceeded recommended lipid intake. Regarding the fiber intake, sixteen (51.6%) 
PKU, 3 (9.7%) MHP children and 2 (6.5%) healthy controls were in line with recommendation 
(≥8.4 g/1000 kcals). The World Health Organization (WHO) recommendation for fruit and 
vegetables consumption (≥400g/day) was reached by 8 (25.8%) PKU children and 1(3.1%) 
healthy children, no one of MHP children. 
Overall daily GI and GL of diet and of each meal in PKU, MHP and healthy children are shown 
in Table 3. Overall dietary GI, as well as at breakfast, lunch and dinner, was higher in PKU than 
MHP and healthy children (0.001<p<0.006). Overall dietary GL, as well as at lunch and dinner, 
was higher in PKU than MHP and healthy children (p<0.001). 
Carotid intima media thickness was observed thinner in PKU children than healthy children 
(0.36[0.05] vs 0.41[0.10] mm, respectively, p=0.004). 
Table 4 shows the glucose metabolism in PKU, MHP and healthy children. Glucose metabolism 
variables did not differ among groups (minimum p=0.153), except for blood glucose that was 
lower in PKU children than healthy controls (p=0.003) and HOMA β that was higher in PKU 
children than healthy controls (p= 0.049). The condition of inuslin resistance (HOMA-IR > 3.16) 
was observed in 4 overweight/obese subjects (2 healthy children, 1 PKU and 1 MHP children).  
Regarding blood lipid profile variables, as shown in Table 5, PKU children exhibited lower 
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blood cholesterols, apolipoprotein A1, higher triglyceride levels, triglycerides/HDL ratio and and 
atherogenic index of plasma than MHP and healthy children (maximum p=0.036). Percentages of 
PKU, mild MHP and healthy children with acceptable, borderline, and high/low plasma lipid, 
and apolipoprotein concentrations are shown in table 6. 
Blood vitamins B (folate and vitamin B12) levels were observed higher in PKU children than 
MHP and healthy children, conversely PKU children showed lower homocysteine levels than 
other two groups (p <0.001), as shown in Table 7. Concerning inflammatory variables, hsCRP 
was lower in PKU children than MHP and healthy controls (PKU:1.54[3.38] mg/L, 
MHP:3.93[8.37] mg/L, healthy: 2.13[2.70] mg/L, respectively, p=0.012), whereas no statistical 
difference was found in fecal calprotectin among groups (PKU: 20.52[15.91] mg/kg, MHP: 
27.65[30.66] mg/kg, healthy: 15.01(12.98) mg/kg, p=0.359). Results of physical activity 
questionnaires are shown in table 8. No statistical differences were observed among the three 
groups. 
 
Associations with risk factors 
 
In PKU group inverse associations between dietary glycemic index and Apo B (R = -0.396; p = 
0.024), ApoB/ ApoA1 (R = -0.466; p = 0.012) were observed. When correlation analyses 
between overall glycemic load and cardiovascular risk factors were assessed, positive association 
between overall glycemic load and HOMA (R = 0.411 p = 0.030) and negative association 
between overall glycemic load and QUICKI were found.  
Moreover, correlation analysis between cIMT and potential arteriosclerotic risk factors were 
assessed in PKU group. No associations of cIMT with overall glycemic index and glycemic load 
were observed. Instead, associations of cIMT and BMI z score (R = 0.552; p = 0.001), total 
cholesterol (R = 0.329; p = 0.07), LDL cholesterol (R = 0.358; p = 0.048), insulin (R = 0.423; p 
= 0.022), HOMA-IR index (R = 0.396; p = 0.033), Lp(a) (R = 0.494; p = 0.006), tyg index (R = 
0.374; p = 0.038) were found. The associations between insulin, HOMA-IR index and cIMT 
were significant also after adjustment for gender, age, BMI z score and Tanner stage. 
No association was observed between cIMT and annual mean Phe.  
 3.
 M
et
ab
ol
ic
 p
ro
fi
le
 a
nd
 r
is
k 
of
 c
ar
di
ov
as
cu
la
r 
di
se
as
e 
in
 c
hi
ld
re
n 
w
it
h 
hy
pe
rp
he
ny
la
la
ni
ne
m
ia
.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 6
7 
T
a
b
le
 2
. 
D
ai
ly
 d
ie
ta
ry
 in
ta
ke
 o
f 
en
er
gy
, m
ac
ro
nu
tr
ie
nt
s,
 f
ib
er
, f
ru
it
 a
nd
 v
eg
et
ab
le
s 
in
 p
he
ny
lk
et
on
ur
ic
 (
P
K
U
),
 m
il
d 
hy
pe
rp
he
ny
la
la
ni
ne
m
ic
 (
M
H
P
) 
an
d 
he
al
th
y 
ch
il
dr
en
.  
 
 
P
K
U
 c
h
il
d
re
n
 (
n
=
3
1
) 
M
H
P
 c
h
il
d
re
n
 (
n
=
3
1
) 
H
ea
lt
h
y
 c
h
il
d
re
n
 (
n
=
3
1
) 
P
-v
a
lu
e 
V
a
ri
a
b
le
 
 M
ea
n
 (
S
D
) 
 M
ea
n
 (
S
D
)  
 M
ea
n
 (
S
D
)  
P
k
u
-M
h
p
-
H
ea
lh
ty
 
E
ne
rg
y 
   
kc
al
s 
   
kc
al
s/
kg
 w
ei
gh
t 
 14
43
.5
6(
26
8.
11
) 
57
.2
5(
15
.2
4)
 
 15
28
.1
1(
26
1.
51
) 
58
.2
7(
19
.6
9)
 
 15
06
.8
9(
41
0.
92
) 
56
.4
7(
21
.3
1)
 
 0.
53
9 
0.
78
4 
P
ro
te
in
 
   
g 
   
%
 e
ne
rg
y 
   
g/
kg
 w
ei
gh
t 
 35
.9
6(
10
.5
0)
a,
b 
10
.0
6(
2.
45
)a
,b
 
1.
39
(0
.3
6)
a,
b  
 54
.3
0(
11
.0
9)
a  
14
.2
8(
2.
37
)a
 
2.
07
(0
.8
0)
a  
 54
.5
3(
15
.2
3)
b 
14
.6
5(
2.
81
)b
 
2.
05
(0
.8
4)
b 
 <
0.
00
1*
 
<
0.
00
1*
 
<
0.
00
1*
 
C
ar
bo
hy
dr
at
e 
   
g 
   
%
 e
ne
rg
y 
   
 22
9.
03
(4
6.
61
) 
63
.2
0(
6.
35
)a
,b
 
 21
1.
53
(3
7.
52
) 
55
.4
8(
5.
67
)a
 
 20
1.
30
(6
2.
17
) 
53
.3
5(
7.
31
)b
 
 0.
09
8 
<
0.
00
1*
 
F
at
 
   
g 
   
%
 e
ne
rg
y 
   
 44
.4
6(
15
.5
4)
b 
27
.3
9(
6.
84
)b
 
 52
.8
3(
15
.7
6)
 
30
.6
8(
5.
10
) 
 53
.0
5(
14
.2
3)
b  
32
.0
8(
5.
59
)b
 
 0.
03
7*
 
0.
01
7*
 
F
ib
er
  
   
ov
er
al
l (
g)
 
   
ov
er
al
l (
g)
/1
00
0 
kc
al
 
 14
.0
2(
5.
65
)a
,b
 
10
.0
2(
4.
46
)a
,b
 
 9.
78
(3
.4
9)
a  
6.
41
(1
.8
2)
a  
 9.
27
(3
.1
7)
b  
6.
10
(1
.5
9)
b  
 0.
00
1*
 
<
0.
00
1*
 
F
ru
it
 a
nd
 v
eg
et
ab
le
s 
 
   
ov
er
al
l (
g)
 
   
fr
ui
t (
g)
 
   
ve
ge
ta
bl
es
 (
g)
 
 30
4.
00
(1
50
.0
9)
a,
b  
12
5.
86
(1
07
.6
0)
 
17
8.
15
(7
3.
04
)a
,b
 
 19
3.
65
(8
0.
05
)a
 
11
2.
29
(7
4.
33
) 
81
.3
6(
41
.5
9)
a  
 17
8.
31
(8
2.
16
)b
 
93
.4
0(
73
.5
5)
 
84
.9
1(
60
.1
0)
b  
 0.
00
2*
 
0.
68
3 
<
0.
00
1*
 
   
   
   
M
H
P 
vs
. H
ea
th
y 
ch
il
dr
en
: n
o 
si
gn
if
ic
an
t d
if
fe
re
nc
e 
fo
r 
an
y 
di
et
ar
y 
va
ri
bl
es
. 
   
   
   
   
 a
 p
<
0.
05
 f
or
 P
K
U
 v
s.
 M
H
P 
ch
il
dr
en
. 
   
   
   
   
   
   
   
   
   
   
   
  b
 p
<
0.
05
 f
or
 P
K
U
 v
s.
 H
ea
lt
hy
 c
hi
ld
re
n.
 
   
   
   
   
   
   
   
 *
 S
ta
ti
st
ic
al
ly
 s
ig
ni
fi
ca
nt
 3.
 M
et
ab
ol
ic
 p
ro
fi
le
 a
nd
 r
is
k 
of
 c
ar
di
ov
as
cu
la
r 
di
se
as
e 
in
 c
hi
ld
re
n 
w
it
h 
hy
pe
rp
he
ny
la
la
ni
ne
m
ia
.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 6
8 
T
a
b
le
 3
. 
G
ly
ce
m
ic
 in
de
x 
an
d 
gl
yc
em
ic
 lo
ad
 o
f 
ov
er
al
l d
ai
ly
 d
ie
t a
nd
 m
ea
ls
 in
 p
he
ny
lk
et
on
ur
ic
 (
P
K
U
),
 m
il
d 
hy
pe
rp
he
ny
la
la
ni
ne
m
ic
 (
M
H
P
) 
an
d 
he
al
th
y 
ch
il
dr
en
. 
 
P
K
U
 c
h
il
d
re
n
  
M
H
P
 c
h
il
d
re
n
  
H
ea
lt
h
y
 c
h
il
d
re
n
  
P
-v
a
lu
e 
V
a
ri
a
b
le
 
M
ea
n
 (
S
D
) 
M
ed
ia
n
[2
5
th
;7
5
th
] 
M
ea
n
 (
S
D
) 
M
ed
ia
n
[2
5
th
;7
5
th
] 
M
ea
n
 (
S
D
) 
M
ed
ia
n
[2
5
th
;7
5
th
] 
P
k
u
-M
h
p
-
H
ea
lh
ty
 
G
ly
ce
m
ic
 i
n
d
e
x
 
O
ve
ra
ll
 d
ie
t 
64
.4
(7
.9
3)
a,
b 
63
.3
8 
[5
9.
03
;6
6.
51
] 
54
.9
2(
4.
22
)a
,c
 
54
.5
8[
52
.9
1;
55
.7
4]
 
51
.0
1(
4.
25
)b
,c
 
50
.8
6[
48
.6
2;
53
.2
7]
 
<
0.
00
1*
 
B
re
ak
fa
st
 
56
.5
0(
30
.4
8)
b 
52
.9
7[
45
.3
5;
56
.6
5]
 
54
.3
5(
30
.7
6)
c  
48
.3
8[
40
.5
7;
55
.7
6]
 
39
.1
7(
11
.6
8)
b,
c  
43
.2
7[
29
.6
2;
47
.3
3]
 
0.
00
1*
 
M
or
ni
ng
 s
na
ck
§  
47
.3
6(
17
.4
3)
 
41
.2
7[
35
.4
3;
61
.6
5]
 
53
.9
6(
11
.9
8)
 
52
.0
0[
47
.5
6;
63
.2
6]
 
43
.3
8(
18
.9
3)
 
46
.0
7[
31
.1
5;
62
.0
0]
 
0.
16
1 
L
un
ch
  
69
.1
1(
6.
70
)a
,b
 
70
.9
4[
63
.7
6;
75
.0
6]
 
55
.5
3(
8.
69
)a
 
54
.3
8[
49
.9
7;
59
.5
0]
 
52
.3
8(
9.
59
)b
 
54
.9
2[
49
.8
6;
57
.9
9]
 
<
0.
00
1*
 
A
ft
er
no
on
 s
na
ck
§§
 
49
.6
1(
10
.9
3)
a  
48
.3
1[
41
.0
9;
56
.3
5]
 
56
.9
2(
9.
86
)a
,c
 
55
.0
0[
50
.8
5;
61
.3
0]
 
49
.6
5(
9.
24
)c
 
49
.6
8[
44
.8
8;
55
.4
8]
 
0.
01
6*
 
D
in
ne
r 
 
69
.6
9(
5.
01
)a
,b
 
69
.5
4[
66
.1
8;
74
.1
7]
 
53
.4
5(
8.
47
)a
 
51
.7
2[
46
.8
2;
61
.7
3]
 
53
.3
3(
10
.5
6)
b 
53
.8
1[
48
.2
0;
58
.0
9]
 
<
0.
00
1*
 
G
ly
ce
m
ic
 l
o
a
d
 
O
ve
ra
ll
 d
ie
t 
14
7.
55
(2
7.
18
) a
,b
 
14
9.
63
[1
25
.3
6;
17
1.
55
] 
11
3.
85
(2
4.
66
)a
 
10
6.
86
[9
9.
54
;1
35
.9
0]
 
10
7.
68
(3
3.
15
)b
 
10
8.
02
[8
3.
85
;1
23
.2
1]
 
<
0.
00
1*
 
B
re
ak
fa
st
 
18
.8
9(
11
.5
3)
 
17
.2
6[
10
.2
2;
25
.4
5]
 
17
.4
4 
(8
.6
7)
 
16
.9
6[
11
.0
0;
22
.0
3]
 
13
.7
9(
9.
62
) 
11
.6
0[
5.
74
;2
0.
54
] 
0.
12
5 
M
or
ni
ng
 s
na
ck
§  
7.
43
(7
.6
1)
 
4.
69
[1
.9
8;
12
.3
6]
 
7.
60
(5
.5
3)
 
5.
38
[2
.8
2;
12
.7
4]
 
8.
15
(6
.6
1)
 
5.
64
[2
.7
6;
15
.3
3]
 
0.
78
7 
L
un
ch
  
53
.1
7(
14
.3
3)
a,
b  
50
.6
3[
41
.5
1;
62
.1
4]
 
37
.5
3(
14
.6
8)
a 
33
.3
6[
26
.3
8;
47
.2
9]
 
40
.0
6(
17
.4
7)
b 
37
.3
3[
30
.9
4;
51
.1
7]
 
<
0.
00
1*
 
A
ft
er
no
on
 s
na
ck
§§
 
15
.3
8(
13
.3
4)
 
10
.3
1[
5.
14
;1
8.
24
] 
16
.3
5(
9.
54
) 
13
.2
8[
8.
79
;2
5.
13
] 
13
.8
3(
8.
26
) 
15
.2
6[
6.
92
;1
9.
50
] 
0.
54
7 
D
in
ne
r 
 
53
.8
0 
(1
9.
48
) a
,b
 
53
.5
5[
43
.3
8;
64
.7
1]
 
38
.6
4(
16
.6
0)
a 
38
.7
4[
24
.4
8;
48
.3
6]
 
34
.8
3(
18
.9
0)
b 
37
.7
1[
18
.9
4;
49
.4
9]
 
<
0.
00
1*
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
§  T
hi
rt
ee
n 
P
K
U
 c
hi
ld
re
n;
 1
4 
M
H
P 
an
d 
14
 h
ea
lt
hy
 c
hi
ld
re
n 
di
d 
no
t r
ep
or
t a
ny
 m
or
ni
ng
 s
na
ck
 d
ur
in
g 
th
e 
fo
od
 d
ia
ry
 r
ec
or
di
ng
. 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
§§
F
ou
r 
P
K
U
 c
hi
ld
re
n;
 4
 M
H
P 
ch
il
dr
en
; 5
 h
ea
lt
hy
 c
hi
ld
re
n 
di
d 
no
t r
ep
or
t a
ny
 a
ft
er
no
on
 s
na
ck
 d
ur
in
g 
th
e 
fo
od
 d
ia
ry
 r
ec
or
di
ng
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
a 
p
<
0.
05
 f
or
 P
K
U
 v
s.
 M
H
P 
ch
il
dr
en
. 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
b 
p
<
0.
05
 f
or
 P
K
U
 v
s.
 H
ea
lt
hy
 c
hi
ld
re
n.
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
c 
p
<
0.
05
 f
or
 M
H
P 
vs
. H
ea
lt
hy
 c
hi
ld
re
n 
   
   
   
   
   
   
   
   
   
   
   
   
 *
St
at
is
ti
ca
ll
y 
si
gn
if
ic
an
t. 
 3.
 M
et
ab
ol
ic
 p
ro
fi
le
 a
nd
 r
is
k 
of
 c
ar
di
ov
as
cu
la
r 
di
se
as
e 
in
 c
hi
ld
re
n 
w
it
h 
hy
pe
rp
he
ny
la
la
ni
ne
m
ia
.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 6
9 
T
a
b
le
 4
. G
lu
co
se
 m
et
ab
ol
is
m
 o
f 
ph
en
yl
ke
to
nu
ri
c 
(P
K
U
),
 M
il
d 
H
yp
er
P
he
ny
la
la
ni
ne
m
ic
 (
M
H
P
) 
an
d 
he
al
th
y 
ch
il
dr
en
. 
 
P
K
U
 c
h
il
d
re
n
  
M
H
P
 c
h
il
d
re
n
  
H
ea
lt
h
y
 c
h
il
d
re
n
  
P
 –
 v
a
lu
e 
V
a
ri
a
b
le
 
M
ea
n
 (
S
D
) 
M
ed
ia
n
 [
2
5
th
;7
5
th
] 
M
ea
n
 (
S
D
) 
M
ed
ia
n
 [
2
5
th
;7
5
th
] 
M
ea
n
 (
S
D
) 
M
ed
ia
n
 [
2
5
th
;7
5
th
] 
P
k
u
-M
h
p
-
H
ea
lh
ty
 
 G
lu
co
se
, m
g/
dL
 
78
.8
1 
(6
.9
0)
b 
79
.0
0[
74
.7
5;
 8
3.
00
] 
78
.4
0(
6.
09
)c
 
79
.0
0[
74
.7
5;
 8
2.
00
] 
84
.3
5(
5.
77
)b
,c
 
86
.0
0[
80
.0
0;
 8
9.
00
] 
  <
0.
00
1*
 
 I
ns
ul
in
, µ
U
/m
L
 
5.
98
 (
3.
85
) 
5.
20
[3
.4
0;
 7
.0
0]
 
5.
84
(2
.9
6)
 
4.
80
[4
.3
0;
5.
80
] 
6.
36
(3
.4
8)
 
5.
70
[4
.2
8;
 8
.2
0]
 
0.
62
1 
H
O
M
A
-I
R
 
1.
18
(0
.8
5)
 
1.
02
[0
.6
6-
1.
29
] 
1.
14
(0
.6
0)
 
0.
93
[0
.8
0-
1.
18
] 
1.
33
(0
.7
8)
 
1.
21
[0
.8
4-
1.
66
] 
0.
28
8 
 H
O
M
A
 β
 
14
8.
47
(7
8.
43
)b
 
12
2.
40
[9
1.
43
;1
74
.8
6]
 
16
1.
70
 (
10
3.
86
)c
 
13
3.
50
[9
9.
66
;2
07
.0
0]
 
11
2.
10
(7
1.
86
)b
,c
 
92
.4
0[
71
.5
5;
12
8.
35
] 
0.
02
1*
 
L
og
 H
O
M
A
-I
R
 
-0
.0
1(
0.
27
) 
0.
01
[-
0.
18
; 0
.1
1]
 
0.
01
(0
.1
8)
 
-0
.0
3[
-0
.1
0;
 0
.0
7]
 
0.
06
(0
.2
4)
 
0.
08
[-
0.
08
; 0
.2
2]
 
0.
28
8 
Q
U
IC
K
 I
nd
ex
 
0.
39
(0
.0
4)
 
0.
38
[0
.3
7;
 0
.4
1]
 
0.
38
(0
.0
3)
 
0.
39
[0
.3
7;
 0
.4
0]
 
0.
38
(0
.0
4)
 
0.
37
[0
.3
5;
 0
.3
9]
 
0.
28
7 
T
ri
gl
yc
er
id
es
/H
D
L
 
 
1.
75
(1
.1
1)
a,
b  
1.
40
[1
.0
6;
 2
.1
1]
 
1.
23
(0
.6
2)
a 
1.
14
[0
.7
6;
 1
.4
3]
 
1.
11
(0
.6
0)
b 
0.
88
[0
.7
8;
 1
.1
9]
 
0.
00
4*
 
T
ri
gl
yc
er
id
e 
G
lu
co
se
 I
nd
ex
   
 
3.
46
(0
.1
8)
 
3.
43
[3
.3
7;
 3
.5
3]
 
3.
38
(0
.1
6)
 
3.
39
[3
.2
9;
 3
.4
8]
 
3.
39
(0
.1
5)
 
3.
38
[3
.2
9;
 3
.4
7]
 
0.
15
3 
   
   
   
   
   
   
   
   
   
 H
O
M
A
-I
R
, h
om
eo
st
at
ic
 m
od
el
 a
ss
es
sm
en
t o
f 
in
su
li
n 
re
si
st
an
ce
; Q
U
IC
K
, q
ua
nt
it
at
iv
e 
in
su
li
n 
se
ns
it
iv
it
y 
ch
ec
k.
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 a
 p
<
0.
05
 f
or
 P
K
U
 v
s.
 M
H
P 
ch
il
dr
en
. 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 b
 p
<
0.
05
 f
or
 P
K
U
 v
s.
 H
ea
lt
hy
 c
hi
ld
re
n.
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 c
 p
<
0.
05
 f
or
 M
H
P 
vs
. H
ea
lt
hy
 c
hi
ld
re
n 
   
   
   
   
   
   
   
   
   
* 
St
at
is
ti
ca
ll
y 
si
gn
if
ic
an
t. 
 3.
 M
et
ab
ol
ic
 p
ro
fi
le
 a
nd
 r
is
k 
of
 c
ar
di
ov
as
cu
la
r 
di
se
as
e 
in
 c
hi
ld
re
n 
w
it
h 
hy
pe
rp
he
ny
la
la
ni
ne
m
ia
.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 7
0 
T
a
b
le
 5
. B
lo
od
 li
pi
d 
pr
of
il
e 
of
 p
he
ny
lk
et
on
ur
ic
 (
P
K
U
),
 M
il
d 
H
yp
er
P
he
ny
la
la
ni
ne
m
ic
 (
M
H
P
) 
an
d 
he
al
th
y 
ch
il
dr
en
. 
 
P
K
U
 c
h
il
d
re
n
  
M
H
P
 c
h
il
d
re
n
  
H
ea
lt
h
y
 c
h
il
d
re
n
  
P
 –
 v
a
lu
e 
V
a
ri
a
b
le
 
M
ea
n 
(S
D
) 
M
ed
ia
n 
[2
5t
h ;
75
th
] 
M
ea
n 
(S
D
) 
M
ed
ia
n 
[2
5t
h ;
75
th
] 
M
ea
n 
(S
D
) 
M
ed
ia
n 
[2
5t
h ;
75
th
] 
P
k
u
-M
h
p
-
H
ea
lh
ty
 
C
ho
le
st
er
ol
 
 
 
 
 
   
T
ot
al
, m
g/
dL
 
13
4.
55
(2
0.
56
)a
,b
 
13
5.
00
[1
21
.0
0;
 1
48
.0
0]
 
15
5.
78
(2
8.
07
)a
 
15
5.
00
[1
33
.0
0;
 1
70
.0
0]
 
16
4.
23
(2
5.
80
)b
 
15
9.
00
[1
48
.0
0;
 1
84
.0
0]
 
<
0.
00
1*
 
   
L
D
L
, m
g/
dL
 
79
.6
1(
15
.8
7)
b  
81
.0
0[
66
.0
0;
 8
8.
00
] 
93
.7
2(
27
.6
4)
 
91
.0
0[
72
.5
0;
11
6.
50
] 
92
.9
4(
22
.4
2)
b  
90
.0
0[
80
.0
0;
 1
06
.0
0]
 
0.
03
6*
 
   
H
D
L
, m
g/
dL
 
50
.0
3(
11
.3
8)
b  
48
.0
0[
38
.0
0;
 5
9.
00
] 
59
.4
2(
24
.7
6)
 
55
.0
0[
45
.7
5;
 6
4.
75
] 
59
.2
9(
11
.0
0)
b  
59
.0
0[
53
.0
0;
 6
5.
00
] 
0.
01
8*
 
   
L
D
L
/H
D
L
 
1.
67
(0
.5
1)
 
1.
62
[1
.2
2;
 2
.0
3]
 
1.
74
(0
.8
1)
  
1.
63
[1
.1
9;
 2
.0
2]
 
1.
62
(0
.4
8)
 
1.
55
[1
.3
4;
 2
.0
5]
 
0.
95
1 
  T
ot
al
/H
D
L
 
2.
79
(0
.5
9)
 
2.
74
[2
.2
0;
 3
.2
4]
 
2.
88
(0
.9
4)
 
2.
78
[2
.3
3;
 3
.2
3]
 
2.
83
(0
.5
5)
 
2.
90
[2
.4
9;
 3
.2
3]
 
0.
85
2 
T
ri
gl
yc
er
id
es
, m
g/
dL
 
80
.1
0(
37
.3
2)
b  
68
.0
0[
60
.0
0;
 8
4.
00
] 
64
.7
0(
21
.3
5)
 
65
.0
0[
51
.0
0;
76
.0
0]
 
61
.3
2(
22
.3
2)
b  
59
.0
0[
48
.0
0;
 7
0.
00
] 
0.
03
7*
 
T
ri
gl
yc
er
id
es
/H
D
L
 
 
1.
75
(1
.1
1)
a,
b  
1.
40
[1
.0
6;
 2
.1
1]
 
1.
23
(0
.6
2)
a  
1.
14
[0
.7
6;
 1
.4
3]
 
1.
11
(0
.6
0)
b  
0.
88
[0
.7
8;
 1
.1
9]
 
0.
00
4*
 
A
th
er
og
en
ic
 I
nd
ex
 o
f 
P
la
sm
a 
 
-0
.1
8(
0.
23
)a
,b
 
-0
.2
2[
-0
.3
3;
 -
0.
04
] 
-0
.3
3(
0.
23
)a
 
-0
.3
1[
-0
.4
8;
 -
0.
21
] 
-0
.3
6(
0.
19
)b
 
-0
.4
2[
-0
.4
7;
 -
0.
29
] 
0.
00
4*
 
A
po
li
po
pr
ot
ei
n 
A
-1
, m
g/
dL
 
12
8.
17
(1
6.
04
)b
 
12
7.
00
[1
14
.7
5;
 1
41
.5
0]
 
13
3.
48
(1
8.
45
) 
13
4.
00
[1
20
.0
0;
 1
48
.0
0]
 
14
3.
88
(1
8.
38
)b
 
14
2.
00
[1
33
.0
0;
 1
56
.0
0]
 
0.
01
1*
 
A
po
li
po
pr
ot
ei
n 
B
, m
g/
dL
 
65
.6
0(
10
.7
6)
 
65
.0
0[
57
.6
5;
 7
2.
25
] 
71
.4
8(
19
.2
0)
 
67
.0
0[
59
.0
0;
 8
5.
00
] 
72
.6
4(
20
.2
7)
 
65
.0
0[
61
.5
0;
 8
4.
00
] 
0.
39
7 
A
po
 B
/A
po
 A
1 
0.
52
(0
.0
9)
 
0.
51
[0
.4
5;
 0
.5
8]
 
0.
55
(0
.1
9)
 
0.
54
[0
.4
0;
 0
.5
9]
 
0.
52
(0
.1
9)
 
0.
45
[0
.3
9;
 0
.5
8]
 
0.
52
6 
L
D
L
/A
po
 B
 
1.
21
 (
0.
10
) 
1.
20
 [
1.
14
;1
.2
7]
 
1.
04
 (
0.
52
) 
1.
26
 [
1.
18
;1
.3
4]
 
1.
32
 (
0.
42
) 
1.
27
 [
1.
16
;1
.5
4]
 
0.
08
4 
L
p(
a)
, m
g/
dL
 
17
.5
4(
21
.8
9)
 
9.
00
[3
.0
0;
 2
1.
50
] 
19
.2
4(
26
.2
5)
 
7.
50
[4
.0
0;
 2
1.
25
] 
17
.2
9(
16
.7
8)
 
8.
50
[4
.0
0;
28
.7
5]
 
0.
81
5 
   
   
   
   
   
   
   
   
   
   
 H
D
L
, H
ig
h-
de
ns
it
y-
li
po
pr
ot
ei
n;
 L
D
L
, L
ow
-d
en
si
ty
-l
ip
op
ro
te
in
; A
po
, A
po
li
po
pr
ot
ei
n;
 L
p(
a)
, L
ip
op
ro
te
in
 (
a)
 
   
   
   
   
   
   
   
   
   
 M
H
P 
vs
. H
ea
th
y 
ch
il
dr
en
: n
o 
si
gn
if
ic
an
t d
if
fe
re
nc
e 
fo
r 
an
y 
va
ri
ab
le
s.
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 a
 p
<
0.
05
 f
or
 P
K
U
 v
s.
 M
H
P 
ch
il
dr
en
. 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 b
p
<
0.
05
 f
or
 P
K
U
 v
s.
 H
ea
lt
hy
 c
hi
ld
re
n.
 
   
   
   
   
   
   
   
   
   
 *
St
at
is
ti
ca
ll
y 
si
gn
if
ic
an
t.
 3.
 M
et
ab
ol
ic
 p
ro
fi
le
 a
nd
 r
is
k 
of
 c
ar
di
ov
as
cu
la
r 
di
se
as
e 
in
 c
hi
ld
re
n 
w
it
h 
hy
pe
rp
he
ny
la
la
ni
ne
m
ia
.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 7
1 
T
a
b
le
 6
. 
N
um
be
r 
(%
) 
of
 p
he
ny
lk
et
on
ur
ic
 (
P
K
U
),
 m
il
d 
hy
pe
rp
he
ni
la
la
ni
ne
m
ic
 (
M
H
P
) 
an
d 
he
al
th
y 
ch
il
dr
en
 w
it
h 
ac
ce
pt
ab
le
, b
or
de
rl
in
e,
 
an
d 
hi
gh
/l
ow
 p
la
sm
a 
li
pi
d,
 a
nd
 a
po
li
po
pr
ot
ei
n 
co
nc
en
tr
at
io
ns
. 
 
P
K
U
 c
h
il
d
re
n
  
M
H
P
 c
h
il
d
re
n
  
H
ea
lt
h
y
 c
h
il
d
re
n
  
 
R
ef
er
en
ce
 v
a
lu
es
 [
2
] 
n
 (
%
) 
n
 (
%
) 
n
 (
%
) 
P
 –
 v
a
lu
e 
T
ot
al
 c
ho
le
st
er
ol
 
   
A
cc
ep
ta
bl
e 
[<
 1
70
 m
g/
dl
] 
 
   
B
or
de
rl
in
e-
hi
gh
 [
17
0-
19
9 
m
g/
dl
] 
   
H
ig
h 
[≥
 2
00
 m
g/
dl
] 
 29
 (
93
.5
)b
 
2 
(6
.5
)b
 
  22
(7
.,0
) 
5 
(1
6.
1)
 
1(
3.
2)
 
  20
 (
64
.5
)b
 
9 
(2
9.
0)
b 
2(
6.
5)
b 
0.
01
9*
 
L
D
L
 c
ho
le
st
er
ol
 
   
A
cc
ep
ta
bl
e 
[<
 1
10
 m
g/
dl
] 
   
B
or
de
rl
in
e 
[1
10
-1
29
 m
g/
dl
] 
   
H
ig
h 
[≥
 1
30
 m
g/
dl
] 
 27
 (
87
.1
)a
 
1 
(3
.2
)a
 
 
  16
 (
51
.6
)a
 
6(
19
.4
)a
 
1(
3.
2)
a 
  25
(8
0.
6)
 
4(
12
.9
) 
2(
6.
5)
 
0.
04
0*
 
A
po
li
po
pr
ot
ei
n 
B
 
   
A
cc
ep
ta
bl
e 
[<
 9
0 
m
g/
dl
] 
   
B
or
de
rl
in
e 
[9
0-
10
9 
m
g/
dl
] 
   
H
ig
h 
[≥
 1
10
 m
g/
dl
] 
  31
(1
00
) 
  25
 (
80
.6
) 
5 
(1
6.
1)
 
1 
(3
.2
) 
  21
(6
7.
7)
 
2(
6.
5)
 
2(
6.
5)
 
0.
28
5 
T
ri
gl
yc
er
id
es
 
  
   
A
cc
ep
ta
bl
e 
[0
-9
y:
 <
 7
5m
g/
dl
;  
   
   
   
   
   
   
   
  1
0-
19
 y
: <
 9
0 
m
g/
dl
] 
 
   
B
or
de
rl
in
e 
[0
-9
y:
 7
5-
99
 m
g/
dl
;  
   
   
   
   
   
   
   
   
10
-1
9 
y:
 9
0-
12
9 
m
g/
dl
] 
 
   
H
ig
h 
[0
-9
y:
 ≥
 1
00
 m
g/
dl
;  
   
   
   
   
10
-1
9 
y:
 ≥
 1
30
 m
g/
dl
] 
 
 19
 (
61
.3
)b
 
 7 
(2
2.
6)
b 
 4 
(1
2.
9)
b 
  2
1(
67
.7
) 
 4(
12
.9
) 
 2(
6.
5)
 
  27
(8
7.
1)
b 
 3(
9.
7)
b 
 
0.
04
8*
 
H
D
L
 c
ho
le
st
er
ol
   
 
   
L
ow
 [
<
 4
0 
m
g/
dl
] 
   
B
or
de
rl
in
e 
[4
0-
45
 m
g/
dl
] 
   
A
cc
ep
ta
bl
e 
[>
 4
5 
m
g/
dl
] 
  8 
(2
5.
8)
 
2 
(6
.5
) 
21
 (
67
.7
) 
 2(
6.
5)
 
4(
12
.9
) 
20
(6
4.
5)
 
   3 
(9
.7
) 
28
 (
90
.3
) 
0.
79
5 
A
po
li
po
pr
ot
ei
n 
A
-1
 
   
L
ow
 [
<
 1
15
 m
g/
dl
] 
   
B
or
de
rl
in
e 
[1
15
-1
20
 m
g/
dl
] 
   
A
cc
ep
ta
bl
e 
[>
 1
20
 m
g/
dl
] 
  7(
22
.6
) 
1(
3.
2)
 
22
(7
1.
0)
 
   6
(1
9.
4)
 
1 
(3
.2
) 
22
(7
1.
0)
  
  1 
(3
.2
) 
 24
 (
77
.4
) 
0.
28
5 
   
   
   
   
 M
H
P 
vs
. H
ea
th
y 
ch
il
dr
en
: n
o 
si
gn
if
ic
an
t d
if
fe
re
nc
e 
fo
r 
an
y 
va
ri
ab
le
. 
   
   
   
   
   
 a
 p
<
0.
05
 f
or
 P
K
U
 v
s.
 M
H
P 
ch
il
dr
en
. 
   
   
   
   
   
  b
p
<
0.
05
 f
or
 P
K
U
 v
s.
 H
ea
lt
hy
 c
hi
ld
re
n.
 
   
   
   
  *
 S
ta
ti
st
ic
al
ly
 s
ig
ni
fi
ca
nt
 3.
 M
et
ab
ol
ic
 p
ro
fi
le
 a
nd
 r
is
k 
of
 c
ar
di
ov
as
cu
la
r 
di
se
as
e 
in
 c
hi
ld
re
n 
w
it
h 
hy
pe
rp
he
ny
la
la
ni
ne
m
ia
.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 7
2 
  
T
a
b
le
 7
. V
as
cu
la
r 
va
ri
ab
le
s 
an
d 
vi
ta
m
in
s 
in
 p
he
ny
lk
et
on
ur
ic
 (
P
K
U
),
 M
il
d 
H
yp
er
P
he
ny
la
la
ni
ne
m
ic
 (
M
H
P
) 
an
d 
he
al
th
y 
ch
il
dr
en
. 
 
P
K
U
 c
h
il
d
re
n
 
M
H
P
 c
h
il
d
re
n
 
H
ea
lt
h
y
 c
h
il
d
re
n
 
P
 –
 v
a
lu
e 
V
a
ri
a
b
le
 
M
ea
n
 (
S
D
) 
M
ed
ia
n
 [
2
5
th
;7
5
th
] 
M
ea
n
 (
S
D
) 
M
ed
ia
n
 [
2
5
th
;7
5
th
] 
M
ea
n
 (
S
D
) 
M
ed
ia
n
 [
2
5
th
;7
5
th
] 
P
k
u
-m
h
p
-
h
ea
lh
ty
 
F
ol
at
e,
 n
g/
m
l 
17
.3
5(
5.
23
)a
,b
 
21
.0
0[
13
.5
3;
 2
1.
00
] 
5.
33
(2
.7
6)
a 
4.
62
[3
.8
0;
 7
.8
5]
 
6.
78
(3
.8
3)
b 
5.
5[
4.
30
;7
.9
7]
 
<
0.
00
1*
 
V
it
am
in
 B
 1
2,
 p
g/
m
L
 
78
3.
30
(2
16
.8
2)
a,
b 
78
6.
50
[6
89
.5
0;
 9
67
.5
0]
 
56
9.
90
(1
79
.8
6)
a 
57
4.
00
[4
38
.0
0;
 7
02
.0
0]
 
55
8.
4(
20
8.
78
)b
 
57
1.
00
[3
80
.7
5;
70
0.
00
] 
<
0.
00
1*
 
H
om
oc
ys
te
in
e,
 µ
m
ol
/L
 
4.
53
(1
.1
7)
 a
,b
 
4.
43
[3
.8
3;
 5
.0
9]
 
6.
76
(1
.7
2)
 a
 
6.
52
[5
.5
0;
 7
.4
9]
 
5.
78
(1
.7
1)
 b
 
5.
5[
4.
55
;6
.6
2]
 
<
0.
00
1*
 
   
   
   
   
   
   
   
   
   
   
  M
H
P 
vs
. H
ea
th
y 
ch
il
dr
en
: n
o 
si
gn
if
ic
an
t d
if
fe
re
nc
e 
fo
r 
an
y 
va
ri
bl
e.
 
   
   
   
   
   
   
   
   
   
   
   
   
   
 a
p
<
0.
05
 f
or
 P
K
U
 v
s.
 M
H
P 
ch
il
dr
en
. 
   
   
   
   
   
   
   
   
   
   
   
   
   
 b
p
<
0.
05
 f
or
 P
K
U
 v
s.
 H
ea
lt
hy
 c
hi
ld
re
n.
 
   
   
   
   
   
   
   
   
  *
St
at
is
ti
ca
ll
y 
si
gn
if
ic
an
t. 
 
T
a
b
le
 8
. P
hy
si
ca
l a
ct
iv
it
y 
of
 p
he
ny
lk
et
on
ur
ic
 (
P
K
U
),
 m
il
d 
hy
pe
rp
he
ni
la
ln
in
em
ic
 (
M
H
P
) 
an
d 
he
al
th
y 
ch
il
dr
en
. 
V
a
ri
a
b
le
 
P
K
U
 c
h
il
d
re
n
 (
n
=
3
1
) 
M
H
P
 c
h
il
d
re
n
 (
n
=
3
1
) 
H
ea
lt
h
y
 c
h
il
d
re
n
 (
n
=
3
1
) 
P
 –
 v
a
lu
e†
 
M
ea
n
(S
D
) 
M
ea
n
(S
D
) 
M
ea
n
(S
D
) 
M
in
ut
es
 s
pe
nt
 w
at
ch
in
g 
T
V
/p
la
yi
ng
 v
id
eo
 g
am
es
 
12
3.
79
 (
56
.9
7)
 
11
2.
57
(7
5.
43
) 
13
3.
18
 (
95
.8
6)
 
0.
64
5 
P
hy
si
ca
l a
ct
iv
it
y 
of
 c
hi
ld
re
n 
≤
 6
 y
ea
rs
 
H
ou
rs
 s
pe
nt
 p
la
yi
ng
 o
ut
si
de
 
2.
96
 (
1.
55
) 
2.
88
 (
1.
21
) 
3.
04
 (
1.
54
) 
0.
99
8 
P
hy
si
ca
l a
ct
iv
it
y 
of
 c
hi
ld
re
n 
>
 6
 y
ea
rs
 
   
T
ot
al
 S
co
re
 
7.
33
 (
1.
10
) 
6.
88
 (
1.
40
) 
6.
48
 (
3.
03
) 
 
  S
po
rt
 S
co
re
 
3.
14
 (
7.
44
) 
3.
03
 (
0.
76
) 
3.
69
 (
1.
28
) 
0.
38
8 
   
L
ei
su
re
 S
co
re
 
2.
63
 (
0.
89
) 
2.
82
 (
0.
76
) 
3.
21
 (
0.
82
) 
0.
08
9 
   
W
or
k 
S
co
re
 
1.
42
 (
0.
58
) 
1.
19
 (
0.
82
) 
1.
02
 (
0.
93
) 
0.
24
6 
   
   
   
   
   
   
   
   
   
   
   
   
   
 †
K
ru
sk
al
 W
al
li
s 
te
st
 o
r 
O
ne
 w
ay
 A
N
O
V
A
.
 3. Metabolic profile and risk of cardiovascular disease in children with hyperphenylalaninemia.                             73 
3.4 Discussion 
 
The aim of this work was to determine cardiovascular risk factors in PKU children, on low-Phe 
diet, in MHP and in healthy children, on unrestricted diet, matched for age, sex and BMI z score 
and to evaluate whether an association may exist between the carbohydrate quality of the diet 
and the risk factors in PKU children.   
The nutritional results, regarding the differences between PKU and healthy children, were in line 
with [17] (Chapter 2). Although daily energy intake was similar between PKU and healthy 
children, PKU children consumed lower proteins and fats, and higher carbohydrates (% of total 
energy) and fibers intakes than healthy children. When PKU diet, phe-restricted diet, was 
compared with MHP unrestricted diet, similar differences (except for no statistical difference 
was observed between the two groups regarding fat intakes) were observed. Overall glycemic 
index and glycemic load of PKU diet were shown higher than MHP and healthy children.  
To our knowledge this is the first study that analyzes cIMT in PKU children. A reduced carotid 
intima media thickness was found in PKU children than healthy children (0.36 [0.05] vs 
0.41[0.10], p=0.004). These findings were in contrast with Htun et al. [35], who evaluated cIMT 
in adult with PKU, they showed no differences between PKU and adult healthy controls 
(0.43[0.02] vs 0.40 [0.01], respectively) [35]. Instead, in accordance with the results observed in 
this study, the carotid intima media thickness of subjects adhering to vegan diet, considered 
similar to PKU diet [36], was observed thinner than subjects adhering to Western diet [37]. 
Differences among the 3 groups regarding blood parameters and fecal calprotectin 
concentrations were analyzed below.  
Regarding blood lipid profile, PKU children showed lower total, LDL, HDL cholesterol levels in 
accordance with previous studies [1,38,39]. Similar results were observed also when lipid profile 
of PKU children was compared with that of MHP children. PKU children recruited in the present 
study had, also, lower Apo A1 levels than healthy children, but this result did not find 
confirmation in literature [1,39]. However, PKU children showed higher triglyceride levels and 
triglycerides/HDL than healthy as observed in previous studies [38,39]. Compared with MHP 
children higher triglyceride levels were observed in PKU children.  These findings may be 
attributed, at least in part, to the PKU diet, which is characterized by avoiding animal foods [40, 
41], and to a higher than the recommended upper limit of carbohydrate intake [34]. Moreover, 
atherogenic index of plasma, a strong predictor of atherosclerosis [32] was observed higher in 
PKU children, although in all groups the mean AIP value was under 0.11, associated with low 
risk of CVD in adults [33]. 
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Consistent with a previously published study [42], our data confirmed decreased plasma Hcy 
levels in PKU patients compared with healthy children and MHP children. In contrast, Schulpis 
et al. showed that PKU patients, on strict diet, had higher Hcy concentrations (moderate 
hyperhomocysteinemia) than healthy children. Certainly, these divergences are determined by 
vitamin B12 and folate levels, both essentials in Hcy metabolism. Indeed, Shulpis et al. [39] 
found low vitamin B12 and folate levels in PKU children, differently from results showed in this 
study.   
No significant difference among groups was found regarding fecal calprotectin concentrations. 
This result was in accordance with the only available study in literature that evaluated the fecal 
calprotectin concentrations in young-adult PKU compared with healthy patients [43], that did not 
observe difference in fecal calprotectin between the two groups.  
Associations between GI/GL and cardiovascular risk factors were assessed in PKU group.  
Inverse associations between dietary glycemic index and Apo B (R = -0.396; p = 0.024), ApoB/ 
ApoA1 (R = -0.466; p = 0.012) were found. In the literature are present only few results on the 
relationship between Apo B and carbohydrate quality [44].  When correlation analyses between 
overall glycemic load and cardiovascular risk factors were assessed, positive association between 
overall glycemic load and HOMA (R = 0.411 p = 0.030) and negative association between 
overall glycemic load and QUICKI were found. No associations between glycemic index and 
glycemic load of the diet and intima media thickness were observed in PKU group. Few studies 
investigated the influence of glycemic index diet on carotid intima media thickness [45,46]. An 
Italian study testing the effect of two hypocaloric diets (high-glycemic vs low-glycemic index 
diet) on weight loss and markers of subclinical atherosclerosis in obese children, observed that 
low glycemic diet performed much better than high glycemic diet in reducing carotid stiffening 
[45]. Instead, a Spanish study that assessed the association between glycemic index and glycemic 
load of the diet and intima media thickness in a population (mean age: 67 years) at high 
cardiovascular risk with no clinical symptoms, did not find significant association between IG or 
CG and cIMT [46].  
Moreover, associations between cIMT and cardiovascular risk factors in PKU group were 
evaluated. Positive associations were observed between insulin, HOMA-IR and cIMT also after 
adjustment for gender, age, BMI z score and Tanner stage. Several observational studies (in 
overweight/obese chidren and in children with diabetes mellitus type 1) demonstrated an 
association between insulin resistance and carotid intima media thickness [47,48]. The 
association between cIMT and insulin resistance was observed also by Fang et al. [49]. They 
explained this association affirming that insulin not only directly stimulates the expression of 
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vascular cell adhesion molecule but disrupts the balance between the production of nitric oxide 
and endothelin-1 leading to endothelial dysfunction [49]. 
Moreover, in PKU group a positive association between cIMT and total, LDL cholesterol was 
found, although it was not significant after confounding factors. Indeed, it is well known in 
literature that carotid IMT is affected by serum lipids [49-51].  
Although a study conducted in 297 healthy children observed an inverse association between 
cIMT and ApoA1 (R = -0.16; p = 0.01) and a positive association with ApoB (R = 0.13; p=0.02) 
and ApoB/ApoA1 ratio (R = 0.15; p = 0.01) at 5 years, in PKU group no associations were 
observed between lipoprotein levels and cIMT [52]. Other studies found, also, associations of 
cIMT with homocysteine levels and physical activity, but in the present study these associations 
were not observed [53,54].  
In conclusion, the nutritional data obtained in this study showed significant differences between 
phe-restricted diet and omnivore diet (followed by MHP and healthy children). Compared with 
MHP and healthy children, PKU children had a higher overall glycemic index and load, fiber and 
carbohydrate intakes and lower protein intakes. Fat intakes of PKU children were lower only 
than healthy children. Regarding cardiovascular risk factors, PKU children showed a thinner 
intima media thickness, lower total cholesterol, LDL cholesterol and homocysteine levels, 
suggesting a lower cardiovascular risk in PKU children than healthy children. Conversely, PKU 
children had higher atherogenic index of plasma, triglyceride levels and higher 
triglycerides/HDL ratio than healthy children. Because PKU children have to start a Phe 
restricted diet as soon as possible and to follow this throughout life, the long-term safety of this 
dietary treatment and its potential impact on later non-communicable diseases risk need to be 
better evaluated.     
Well-designed longitudinal studies, with adequate statistical power, still are needed to hopefully 
clarify the potential underlying mechanisms relating PKU diet and cardiovascular risk factors.
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4.1 Introduction 
 
The aim of this work was to compare gut microbiota biodiversity and its production of short 
chain fatty acids (SCFA) in PKU children, on low-Phe diet, and MHP children, on 
unrestricted diet. It was conducted in collaboration with the Microbiology Unit, Department 
of Health Sciences, University of Milan. They performed gut microbiota analysis.   
 
 
4.2 Materials and methods 
 
This observational case control study included 21 phenylketonuric (PKU) children (age 4-18 
years) gender and age (±12 months) matched with 21 children with mild 
hyperphenylalaninemia (MHP), consecutively admitted to the Department of Pediatrics, San 
Paolo Hospital, Milan, from December 2014 to May 2016.  Inclusion criteria were: 
gestational age 37–42 week inclusive, weight at birth ≥ 2500 g, single birth, white parents. 
Exclusion criteria were: congenital malformation, having endocrine disorders, chronic liver 
diseases, chronic or acute intestinal diseases and treatments with antibiotic and 
probiotic/prebiotic in the previous 3 months. PKU children non-compliant with the 
recommended diet were also excluded. PKU children were defined as compliant to the diet 
when the annual mean Phe levels, monitored monthly by the Guthrie test [1], was within the 
range 120–360 µmol/L for children below 13 years and was under 600 µmol/L for patients 
>13 years. Phenylketonuric children were detected by a newborn screening test and 
periodically monitored in our department since diagnosis.  A medical history was collected at 
recruitment from parents by a standardized questionnaire during a personal interview 
conducted by the same pediatrician that also saw the children for a general examination. 
Moreover, the pediatrician took anthropometric measurements of children, assisted by an 
experienced operator. Body weight and height were measured using a mechanical column 
scale (seca 711; seca GmbH & KG, Hamburg, Germany) with an integrated measuring rod 
(seca 220; seca GmbH & KG). The body mass index (BMI) was calculated from the ratio of 
weight to height squared (kg/m2). BMI z-scores were calculated and adjusted for age and 
gender by using WHO anthro [2].  
A fresh fecal sample was self-collected at home by each enrolled subject and stored 
immediately at -20° C. The collection took place in the same week as the dietary record. 
Subsequently, the fecal samples were transported to the laboratory and stored at -20° C until 
further analysis. The parents of eligible children or their legal guardian received a detailed 
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explanation of the study, and signed a consent form. The hospital Ethics Committee approved 
the study protocol and gave ethical clearance. 
 
 
Dietary assessment  
For each child, the dietary intake, including beverages, was recorded by means of a food 
diary filled out by parents for three consecutive days (two weekdays and one weekend day). 
Parents received instructions about the method for weighing and recording food. They were 
trained by a dietitian to weigh each food item offered to their child before consumption, to 
weigh leftovers and to record the weights each time [3]. Dietary glycemic index and dietary 
glycemic load were performed using a previously described (Chapter 2).  
 
Bacterial DNA extraction 
Total microbial DNA extraction was performed with the Spin Stool DNA Plus Kit (Stratec 
Molecular, Berlin, Germany) according to manufacturer instruction, using 200mg aliquot of 
wet feces. 
The extraction kit provides homogenization of the fecal sample in a lysis buffer and 
incubation at 95° C for 10 minutes. The lysed sample was mixed with the matrix in 
InviAdsorb to remove most of the components that inhibit PCR. Proteinase K was added to 
the supernatant to digest and degrade proteins after incubation at 70° C. The purification of 
bacterial DNA was obtained by the addition of suitable buffers to remove other impurities. 
The filtrate was added with an elution buffer to obtain bacterial DNA in 100 µL. The 
microbial DNA extract concentration and purity were evaluated by NanoDrops 
(Spectrophotometer ND-1000). One microliter of each bacterial DNA extract solution was 
read at a wavelength of 260 nm.  
 
Short Chain Fatty Acid (SCFA) measurement 
 
SCFA concentrations were assessed in accordance with the method proposed by Weaver et 
al. (1997) modified as follows. Stool (200 mg) were suspended in 1 ml of double distilled 
water, homogenized on vortex mixer and, after 30 min, centrifuged (15000 rpm) for 15 min 
at 10° C.  Aliquots (500 μl) of supernatant were added with: 
- 200 μl 85% orthophosphoric acid 
- 200 μl 2% (v/v) sulphuric acid 
- 100 μl 2-ethyl-butyric acid (iSTD, Aldrich cat n 245526) 10 mM in HCOOH 12% as 
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internal standard. SCFA were gently extracted for 1 min with 1 ml ethyl-ether/heptan (1:1 
v/v) and centrifuged for 10 min at 3000 rpm. The aqueous phase was frozen and the organic 
layer was removed for analysis by a Varian 3400 CX gas liquid chromatograph equipped 
with a Varian 8200 CX autosampler and a HP-FFAP fused-silica capillary column (30 m, 
0.53 mm i.d. with a 1-mm film). Specific chromatography conditions were: gas carrier He 
with flow 15 ml/min; splitting 1:10 after 20 seconds injection; injection volume of 1 μl. 
Injector and detector temperatures were 110 and 260° C, respectively. The initial oven 
temperature was 60° C and was increased by 10° C min-1 to 110° C and then by 5° C min-1 
and held at 200 for 5 min. Quantification of the SCFA was obtained through calibration 
curves of acetic, propionic, iso-butyric, butyric and iso-valeric acid in concentrations 
between 0.25 mM and 10 mM (10 mM 2-ethyl-butyric acid as internal standard). 
 
Absolute quantification analyses in real time PCR (qRT-PCR) 
 
The quantitative analysis of fecal DNA was carried out on the main of short-chain fatty acids 
producing species using Real Time PCR technique (qRT-PCR). The amplification reaction 
was conducted using as detector system SYBR® Green I dye, a DNA intercalating agent 
that has a minimal fluorescence in the initial mixture and emits fluorescence at 520 nm only 
when it is bound to dsDNA. Therefore, fluorescence intensity depends on the initial amount 
of the sample. The fluorescence emission during the PCR amplification was analyzed by 
SDS, Sequence Detection System software, which constructed amplification curve. The 
measurements, from the 3rd to the 15th cycle, were considered background noise (basic 
level) and on these standard deviations were calculated. The threshold cycle values were 
calculated by determining the point at which the fluorescence exceeds 10 times the standard 
deviation of the basic level. To determine the initial concentration of the sample, software 
calculated the threshold cycle of each sample and places this value in a standard curve of 
precisely known concentration a standard (Figure 1). 
After DNA extraction with Prepman Ultra kit (Applied Biosystems, USA), the standard 
curve was determined by the following control strains: roseburia intestinalis DSM 14610 
and DSM 17677 Faecalibacterium prausntzii of international collection DSMZ (Leibniz-
Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH). 
Absolute quantification by real-time PCR was performed using the following control strains: 
uniformis Bacteroides, Lactobacillus reuteri and Bifidobacterium animali (from Clinical 
Microbiology Laboratory of the Department of Health Sciences of the University of Milan).  
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Statistical analysis  
Variables were expressed as mean (standard deviation, SD). Statistical analysis was 
performed using ANOVA (for the comparison of variables between groups) and Whitney U-
test (for comparison between subjects), using the statistical software Graph Pad Prism (Graph 
Pad Software, Inc., La Jolla, CA, USA). All adjusted values of p < 0.05 were considered 
statistically significant (two-tailed test).
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4.3 Results  
 
21 PKU and 21 MHP children were enrolled in the study, 10 boys and 11 girls for each 
group. Mean (SD) age of children was 8.81 (3.59) years. No significant differences in 
anthropometric parameters (weight, age and BMI z score) and mean blood Phe level were 
observed between PKU and MHP children (Table 1). 
 
Table 1. Anthropometric parameters and blood Phenylalanine (Phe) levels in     
phenylketonuric (PKU) and mild hyperphenylalaninemic (MHP) children. 
 PKU children 
(n=21) 
MHP children 
(n=21) P-value 
Variable Mean (SD) Mean (SD)  
Blood Phe levels, µmol/L 263.8 (95.1) 222.1 (74.7) 0.120 
Weight, kg 35.5 (10.9) 29.9 (13.4) 0.068 
Height, m 1.38 (0.17) 1.29 (0.17) 0.182 
BMI, z-score 0.45 (1.26) 0.30 (0.98) 0.534 
 
 
 
Dietary intake of energy, macronutrients, fiber, fruit and vegetables are reported in Table 2. 
PKU children consumed lower proteins and higher carbohydrates (% of total energy) and 
fibers than MHP and healthy children (0.001<p<0.022). Moreover, PKU consumed a 
higher fruit and vegetables (overall and only vegetables) intakes than MHP.  
Overall daily GI and GL of diet and of each meal in PKU and in MHP children are shown 
in Table 3. Overall dietary GI, as well as at lunch and dinner, was higher in PKU than MHP 
children (0.001<p<0.002). Overall dietary GL, as well as at lunch and dinner, was higher in 
PKU than MHP children (p<0.001).
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Table 2. Daily dietary intake of energy, macronutrients, fiber, fruit and vegetables in 
children with phenylketonuria (PKU) and with mild hyperphenylalaninemia (MHP). 
Variable 
PKU children 
(n=21) 
 MHP children 
(n=21) 
P-value 
 
Mean (SD) 
 
Mean (SD) 
Energy 
   kcals    
   kcals/kg weight 
 
1673.49 (430.20) 
 49.16(9.96) 
 
1472.23 (312.04) 
50.96(24.48) 
 
0.171 
0.531 
Protein 
   total, g 
   % energy 
   g/kg weight 
   from vegetables, g 
   from animal sources, g 
   from formula, g 
 
43.21 (14.77) 
10.32 (1.86) 
1.26(0.31) 
7.49(2.23) 
4.76(3.28) 
28.70(12.67) 
 
51.37(11.16) 
14.26 (2.27) 
1.78(0.79) 
16.68(5.37) 
27.57(8.62) 
0(0) 
 
0.022* 
<0.001* 
0.070 
<0.001* 
<0.001* 
<0.001* 
Carbohydrate 
   g 
   % energy    
 
252.90 (71.19) 
60.98 (6.97) 
 
207.57(47.07) 
56.45 (6.97) 
 
0.060 
0.042* 
Fat 
   g 
   % energy    
 
54.60(15.67) 
30.66 (8.10) 
 
50.80 (15.46) 
32.31 (4.75) 
 
0.531 
0.135 
Fiber  
   overall, g 
   overall, g/1000 kcal 
 
15.79 (8.95) 
9.58(4.82) 
 
8.87 (2.74) 
6.15(1.84) 
 
0.002* 
0.021* 
Fruit and vegetables  
   overall, g 
   fruit, g 
   vegetables, g 
 
373.03(194.30) 
138.76 (127.46) 
234.27 (116.93) 
 
199.71(80.30) 
119.81 (55.85) 
79.93 (50.85) 
 
0.004* 
0.867 
<0.001* 
              * Statistically significant
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Table 3. Glycemic index and glycemic load of overall daily diet and meals in children with 
phenylketonuria (PKU) and with mild hyperphenylalaninemia (MHP).  
 
Variable 
PKU children 
(n=22) 
MHP children 
(n=22) P - value 
 
Mean (SD) 
 
Mean (SD)  
Glycemic index 
Overall diet 64.82 (5.29) 52.78 (3.78) <0.001* 
Breakfast 51.38 (19.34) 47.03 (9.63) 0.249 
Morning snack§ 44.64 (23.45) 47.16 (24.11) 0.491 
Lunch  68.99 (9.12) 54.11 (7.48) <0.001* 
Afternoon snack  46.06 (14.45) 51.70 (9.24) 0.067 
Dinner  68.53 (5.67) 64.66 (41.25) 0.002 
After-dinner snack 18.91 (14.49) 43.44 (15.23) 0.117 
Glycemic load 
Overall diet 165.11 (47.57) 104.09 (29.79) <0.001* 
Breakfast 14.80 (8.15) 15.72 (6.75) 0.819 
Morning snack§ 9.55 (8.95) 4.03 (4.25) 0.141 
Lunch  61.11 (21.97) 33.47 (15.22) <0.001* 
Afternoon snack  18.01 (12.76) 14.91 (10.93) 0.526 
Dinner  61.75 (23.85) 36.43 (17.53) 0.001 
After-dinner snack 5.24 (4.96) 3.24 (2.63) 0.648 
             §Four PKU children and 10 MHP children did not report any morning snack during the  
food diary recording. 
         * Statistically significant.
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Quantification of short chain fatty acids (SCFA) 
 
In Table 4 are reported fecal short chain fatty acids (SCFA) concentrations in children 
with phenylketonuria (PKU) and with mild hyperphenylalaninemia (MHP). 
 
 
        Table 4 SCFA(mg/g) in children with PKU 
         and with mild hyperphenulalaninemia MHP. 
SCFA PKU children  MHP children   
 mg/g of faeces Mean (SD) Mean (SD) 
acetate 3.0 (0.8) 3.6 (1.3) 
propionate 1.1(0.4) 1.1(0.4) 
i-butyrate 0.2(0.1) 0.2(0.1) 
butyrate 1.0(0.3)* 1.3(0.4)* 
i-valerate 0.3(0.2) 0.3(0.2) 
Total 5.5(1.1)* 6.5(1.4)* 
                                           SD:Standard Deviation 
                                                   *Statistically significant 
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PKU children showed lower total fecal SCFA and butyrate production than MHP children  
 (p=0.04 e p=0.02, respectively), Figure 1.  No differences were observed between the two 
groups regarding acetate, propionate, butyrate, iso-butyrate and iso-valerate. 
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Absolute quantification analyses in real time PCR (qRT-PCR) 
 
Real-Time PCR was performed to quantify the abundance of the two major groups of butyrate-
producing bacteria. These analyses showed a significant reduction of Faecalibacterium 
prausnitzii species and Roseburia spp. (p = 0.02 and p = 0.03, respectively) in PKU compared 
with MHP children (Figure 2 A-B). 
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Figure 2.  Microbial quantification, in phenylketonuric (PKU, red) 
and mild hyperphenylalaninemia (MHP, blue) children, of 
Faecalibacterium prausnitzii (A), and Roseburia spp (B).  
Abundances are expressed as log10 genome copies/g faeces.  
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qRT-PCR was also performed to evaluate possible differences in the abundance of two genera of 
lactate-producing bacteria (Bifidobacterium spp. e Lactobacillus spp).  
PKU children showed a decrease in Lactobacillus spp. compared with MHP children (p=0.002) 
(Fig.3). No significant differences were observed for Bifidobacterium spp. 
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Figure 2.  Lactobacillus spp. abundances (log10 genome copies/g 
faeces) in phenylketonuric (PKU, red) and mild 
hyperphenylalaninemia (MHP, blue) children. 
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4.4 Discussion 
 
The aim of this work was to compare gut microbiota biodiversity and its production of short 
chain fatty acids (SCFA) in PKU children, on low-Phe diet, and MHP children, on unrestricted 
diet. Nutritional results showed differences in protein, carbohydrate and fiber intakes between 
PKU and MHP children, although similar energy intakes were observed in the two experimental 
groups. Specifically, PKU children showed a lower protein and higher carbohydrate and fiber 
intakes compared with MHP children. Moreover, vegetables intake, daily glycemic index and 
glycemic load were higher in PKU than MHP children.  
Because changes in diet could result in different substrates for microbial fermentation, the main 
microbial metabolites, short chain fatty acids, were measured.  
Acetate, butyrate, and propionate derive mainly from carbohydrates fermentation, whereas 
branched-chain fatty acids (BCFAs, 5% of total SCFAs), mainly iso-butyrate and iso-valerate, 
from proteins and amino acids fermentation by proteolytic bacteria [4]. 
Total fecal SCFA, as well as butyrate were decreased in PKU compared with MHP children. No 
differences were observed for acetate, propionate, and BCFAs. 
Butyrate is the preferred energy source for colonocytes, and participates in maintaining gut 
homeostasis. Several families belonging to Firmicutes have a key role in butyrate production, 
especially Faecalibacterium prausnitzii, and Eubacterium rectale/Roseburia group [5]. Absolute 
quantification by qRT PCR showed decrease of both F. prausnitzii and Roseburia spp. as well as 
of Lactobacillus spp.. The latters produce lactate that can be further used as substrate for butyrate 
production. 
These results seem to confirm what predicted by Pinheiro de Oliveira F and colleagues [6], 
which conducted the only available study in literature on PKU gut microbiota (a controlled study 
based on next-generation sequencing). The authors observed the presence of distinct bacterial 
taxonomic groups between PKU and healthy children and, according to metagenome prediction 
analysis, PKU microbiota presented fewer genes encoding for enzymes involved in starch and 
sucrose metabolism and in glycolysis/gluconeogenesis. 
A reduction in SCFA production seems inconsistent with the higher fiber and vegetable (rich 
fiber foods) intakes that characterize PKU diets. Indeed, fibers are non-digestible carbohydrates 
that are fermented in the cecum and the large intestine by the anaerobic cecal and colonic 
microbiota allowing the production of short-chain fatty acids [7]. However, also the quality of 
fibers is a key factor in determining gut microbiota composition and its SCFA production. 
Studies highlighted that dietary fibers have a greater range of structures that could affect the gut 
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microbiota in different ways (bacteria use different metabolic methods to break down the sugar) 
[8]. Furthermore, Benus and colleagues, investigating the effect of dietary fiber exclusion and 
supplementation on the intestinal microbiota and SCFA concentrations in healthy subjects, 
observed large and statistically significant reductions in the abundance of Faecalibacterium 
prausnitzii and Roseburia spp. groups (butyrate producing bacteria analyzed also in the present 
study) during both fiber-free and fiber-supplemented diets. The authors demonstrated significant 
and strong positive correlations between F. prausnitzii abundance and fecal butyrate 
concentrations, and suggested that reduction of Roseburia spp. and F. prausnitzii during fiber-
supplemented diet may be related to fibers that do not promote their proliferation [9].  
DGGE analysis of fecal samples examined in this PhD thesis (data not shown) demonstrated a 
lower degree of microbial diversity in gut microbiota of PKU compared with MHP children. A 
reduced microbial richness is considered the first hallmark of gut dysbiosis. Changes in 
microbial population in PKU children results in altered SCFA production that could impact on, 
intestinal permeability.  
In conclusion, the restricted PKU diet, characterized by a higher carbohydrate intake, including 
many simple sugars and non-digestible fiber, has been shown to increase glycemic index and 
glycemic load, resulting in a different quality of substrate for microbial fermentation.  
Further studies using innovative sequencing techniques are needed to better investigate gut 
microbiota dysbiosis in PKU children and to eventually pave the way for pre/probiotic 
supplementations. 
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